RCC
MCID: RNL014
MIFTS: 82

Renal Cell Carcinoma (RCC) malady

Categories: Genetic diseases, Rare diseases, Nephrological diseases, Cancer diseases

Aliases & Classifications for Renal Cell Carcinoma

About this section

Aliases & Descriptions for Renal Cell Carcinoma:

Name: Renal Cell Carcinoma 52 35 11 48 24 70 27 13 68
Adenocarcinoma of Kidney 11 48 24 70
Hereditary Clear Cell Renal Cell Carcinoma 54 68
Renal Carcinoma, Chromophobe, Somatic 52 12
Renal Cell Carcinoma Non-Papillary 70 27
Nonpapillary Renal Cell Carcinoma 11 13
Hypernephroma 11 70
Rcc 11 70
Hereditary Clear Cell Renal Cell Adenocarcinoma 54
Renal Cell Carcinoma, Clear Cell, Somatic 52
Conventional Renal Cell Carcinoma 68
 
Renal Cell Carcinoma, Nonpapillary 52
Conventional Renal Cell Carcinoma 70
Renal Cell Carcinoma, Somatic 52
Common Renal Cell Carcinoma 70
Clear Cell Renal Carcinoma 70
Renal Cell Adenocarcinoma 48
Carcinoma, Renal Cell 39
Carcinoma Renal Cell 50
Ccrcc 70
Crcc 70

Characteristics:

Orphanet epidemiological data:

54

HPO:

64
renal cell carcinoma:
Inheritance: sporadic

Classifications:

Orphanet: 54 
Rare renal diseases


External Ids:

OMIM52 144700
Disease Ontology11 DOID:0050387, DOID:4450
MeSH39 D002292
NCIt45 C9385
Orphanet54 ORPHA422526
ICD10 via Orphanet31 C64

Summaries for Renal Cell Carcinoma

About this section
OMIM:52 The Heidelberg histologic classification of renal cell tumors subdivides renal cell tumors into benign and malignant... (144700) more...

MalaCards based summary: Renal Cell Carcinoma, also known as adenocarcinoma of kidney, is related to sarcomatoid renal cell carcinoma and renal clear cell carcinoma, and has symptoms including flank pain, flank pain and flank pain. An important gene associated with Renal Cell Carcinoma is RNF139 (Ring Finger Protein 139), and among its related pathways are Development HGF signaling pathway and Pathways in cancer. The drugs medroxyprogesterone acetate and medroxyprogesterone have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and t cells, and related mouse phenotypes are homeostasis/metabolism and hematopoietic system.

Disease Ontology:11 A renal carcinoma that has material basis in the lining of the proximal convoluted renal tubule of the kidney.

Novus Biologicals:51 Renal cell carcinoma originates in the proximal renal tube and is the most common form of kidney cancer. Renal cell carcinoma is resistant to radiation therapy and chemotherapy, however some cases respond to immunotherapy. Interleukin-2 has produced remission in some patients, as has functional restoration of the VHL gene.

UniProtKB/Swiss-Prot:70 Renal cell carcinoma: Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into clear cell renal carcinoma (non- papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma. Clear cell renal cell carcinoma is the most common subtype.

Wikipedia:71 Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted... more...

Related Diseases for Renal Cell Carcinoma

About this section

Diseases in the Renal Cell Carcinoma family:

Hereditary Renal Cell Carcinoma Renal Clear Cell Carcinoma
Renal Cell Carcinoma 4

Diseases related to Renal Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 390)
idRelated DiseaseScoreTop Affiliating Genes
1sarcomatoid renal cell carcinoma33.9CA9, FHIT, HIF1A, VEGFA, VHL
2renal clear cell carcinoma33.2DIRC2, FH, FHIT, FLCN, MET, RNF139
3renal cell carcinoma, papillary12.6
4clear cell renal cell carcinoma12.4
5chromophobe renal cell carcinoma12.4
6clear cell papillary renal cell carcinoma12.3
7tubulocystic renal cell carcinoma12.2
8hereditary renal cell carcinoma12.1
9chromophil renal cell carcinoma12.0
10eosinophilic variant of chromophobe renal cell carcinoma12.0
11renal cell carcinoma 412.0
12acquired cystic disease-associated renal cell carcinoma11.9
13multilocular clear cell renal cell carcinoma11.9
14mucinous tubular and spindle renal cell carcinoma11.9
15hereditary conventional renal cell carcinoma11.9
16renal cell carcinoma associated with neuroblastoma11.9
17leiomyomatosis and renal cell cancer11.8
18classic variant of chromophobe renal cell carcinoma11.8
19von hippel-lindau syndrome11.5
20collecting duct carcinoma11.4
21renal oncocytoma11.2
22kidney cancer11.2
23metanephric adenoma11.1
24birt-hogg-dube syndrome11.1
25varicocele11.1
26melanoma, cutaneous malignant 811.0
27childhood kidney cell carcinoma11.0
28multilocular cystic clear cell renal cell neoplasm of low malignant potential11.0
29cowden syndrome 210.8
30tumor predisposition syndrome10.8
31cowden syndrome 510.8
32tuberous sclerosis-110.8
33cowden syndrome 410.8
34cowden syndrome 110.8
35cowden syndrome 310.8
36cowden syndrome 610.8
37cowden syndrome 710.8
38thyroid carcinoma, papillary, with papillary renal neoplasia10.5CA9, FH, FLCN, MET, PRCC, TFE3
39cleft palate cardiac defect ectrodactyly10.5CA9, EPAS1, FLCN, HIF1A, MET, OGG1
40endotheliitis10.5
41central nervous system leiomyosarcoma10.5CA9, EPAS1, HIF1A, VEGFA, VHL
42ovarian brenner tumor10.5CA9, EPAS1, FH, FHIT, FLCN, HIF1A
43rectum kaposi's sarcoma10.5FH, FLCN, HIF1A, MET
44complement deficiency10.5FH, FLCN, MET
45mini stroke10.5CA9, EPAS1, HIF1A, VEGFA, VHL
46erythrocytosis, familial, 210.5HIF1A, MET, VEGFA, VHL
47gtp cyclohydrolase 1-deficient dopa-responsive dystonia10.5FH, HIF1A, VHL
48generalized eruptive keratoacanthoma10.5CA9, TFE3, VHL
49atrioventricular septal defect 210.5EPAS1, HIF1A, VHL
50neuropathy with hearing impairment10.5TFE3, VEGFA, VHL

Graphical network of the top 20 diseases related to Renal Cell Carcinoma:



Diseases related to renal cell carcinoma

Symptoms & Phenotypes for Renal Cell Carcinoma

About this section


Clinical features from OMIM:

144700

Human phenotypes related to Renal Cell Carcinoma:

 64
id Description HPO Frequency HPO Source Accession
1 renal cell carcinoma64 HP:0005584

UMLS symptoms related to Renal Cell Carcinoma:


flank pain

MGI Mouse Phenotypes related to Renal Cell Carcinoma according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000537611.4EPAS1, FH, FHIT, FLCN, HIF1A, HNF1A
2MP:000539711.4CA9, EPAS1, FHIT, FLCN, HIF1A, IL2
3MP:000538111.4CA9, FHIT, HIF1A, HNF1A, IL2, MET
4MP:000538711.4CA9, EPAS1, FHIT, FLCN, HIF1A, HNF1B
5MP:001076811.4CA9, EPAS1, FH, FHIT, FLCN, HIF1A
6MP:000537011.4EPAS1, HIF1A, HNF1A, HNF1B, IL2, MET
7MP:000536911.3EPAS1, HIF1A, HNF1A, HNF1B, MET, VEGFA
8MP:000200611.3FHIT, FLCN, HIF1A, IL2, MET, OGG1
9MP:000536710.6FH, FLCN, HIF1A, HNF1A, HNF1B, MET

Drugs & Therapeutics for Renal Cell Carcinoma

About this section

FDA approved drugs:

(show all 8)
id Drug Name Active Ingredient(s)16 Company Approval Date
1
Afinitor 16 44 EVEROLIMUS Novartis March 2009
FDA Label: Afinitor
Disease/s that Drug Treats:renal cell carcinoma/ renal angiomyolipoma associated with tuberous sclerosis complex/ advanced pancreatic neuroendocrine tumors/ hormone receptor-positive, HER2-negative breast cancer
Indications and Usage:16 AFINITOR is a kinase inhibitor indicated for the treatment of: postmenopausal women with advanced hormone receptor-positive, HER2- negative breast cancer (advanced HR+ BC) in combination with exemestane after failure of treatment with letrozole or anastrozole. (1.1) adults with progressive neuroendocrine tumors of pancreatic origin (PNET) that are unresectable, locally advanced or metastatic. AFINITOR is not indicated for the treatment of patients with functional carcinoid tumors. (1.2) adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. (1.3) adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. The effectiveness of AFINITOR in the treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months. Further follow-up of patients is required to determine long-term outcomes. (1.4) AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the treatment of: pediatric and adult patients with tuberous sclerosis complex (TSC) who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. The effectiveness is based on demonstration of durable objective response, as evidenced by reduction in SEGA tumor volume. Improvement in diseaserelated symptoms and overall survival in patients with SEGA and TSC has not been demonstrated. (1.5)
DrugBank Targets:14 Serine/threonine-protein kinase mTOR
Mechanism of Action:16 
Target: mTOR
Action: inhibitor
FDA: Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of thePI3K/AKT pathway. The mTOR pathway is dysregulated in several human cancers. Everolimus binds to an intracellularprotein, FKBP-12, resulting in an inhibitory complex formation with mTOR complex 1 (mTORC1) and thus inhibition ofmTOR kinase activity. Everolimus reduced the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic initiationfactor 4E-binding protein (4E-BP1), downstream effectors of mTOR, involved in protein synthesis. S6K1 is a substrate ofmTORC1 and phosphorylates the activation domain 1 of the estrogen receptor which results in ligand-independentactivation of the receptor. In addition, everolimus inhibited the expression of hypoxia-inducible factor (e.g., HIF-1) andreduced the expression of vascular endothelial growth factor (VEGF). Inhibition of mTOR by everolimus has been shownto reduce cell proliferation, angiogenesis, and glucose uptake in in vitro and/or in vivo studies.Constitutive activation of the PI3K/Akt/mTOR pathway can contribute to endocrine resistance in breast cancer. In vitrostudies show that estrogen-dependent and HER2+ breast cancer cells are sensitive to the inhibitory effects of everolimus,and that combination treatment with everolimus and Akt, HER2, or aromatase inhibitors enhances the anti-tumor activityof everolimus in a synergistic manner.Two regulators of mTORC1 signaling are the oncogene suppressors tuberin-sclerosis complexes 1 and 2 (TSC1, TSC2).Loss or inactivation of either TSC1 or TSC2 leads to activation of downstream signaling. In TSC, a genetic disorder,inactivating mutations in either the TSC1 or the TSC2 gene lead to hamartoma formation throughout the body.
2
Avastin16 44 BEVACIZUMAB Genentech July 2009
FDA Label: Avastin
Disease/s that Drug Treats:renal cell carcinoma & Colorectal Cancer
Indications and Usage:16 Avastin is a vascular endothelial growth factor-specific angiogenesisinhibitor indicated for the treatment of: Metastatic colorectal cancer, with intravenous 5-fluorouracil-basedchemotherapy for first- or second-line treatment. (1.1) Metastatic colorectal cancer, with fluoropyrimidine- irinotecan- orfluoropyrimidine-oxaliplatin-based chemotherapy for second-linetreatment in patients who have progressed on a first-line Avastincontainingregimen. (1.1) Non-squamous non-small cell lung cancer, with carboplatin and paclitaxelfor first line treatment of unresectable, locally advanced, recurrent ormetastatic disease. (1.2) Glioblastoma, as a single agent for adult patients with progressive diseasefollowing prior therapy. (1.3)-Effectiveness based on improvement in objective response rate. No dataavailable demonstrating improvement in disease-related symptoms orsurvival with Avastin. Metastatic renal cell carcinoma with interferon alfa (1.4) Cervical cancer, in combination with paclitaxel and cisplatin or paclitaxeland topotecan in persistent, recurrent, or metastatic disease. (1.5) Platinum-resistant recurrent epithelial ovarian, fallopian tube or primaryperitoneal cancer, in combination with paclitaxel, pegylated liposomaldoxorubicin or topotecan (1.6) Limitation of Use: Avastin is not indicated for adjuvant treatment of coloncancer. (1.1)
DrugBank Targets:14 1. Vascular endothelial growth factor A;2. Low affinity immunoglobulin gamma Fc region receptor III-B;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Low affinity immunoglobulin gamma Fc region receptor III-A;8. High affinity immunoglobulin gamma Fc receptor I;9. Low affinity immunoglobulin gamma Fc region receptor II-a;10. Low affinity immunoglobulin gamma Fc region receptor II-b;11. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:16 
Target: VEGF
Action: inhibitor
FDA: Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR)697 on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial698 cell proliferation and new blood vessel formation in in vitro models of angiogenesis. Administration699 of bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction700 of microvascular growth and inhibition of metastatic disease progression
3
Inlyta16 44 AXITINIB Pfizer January 2012
FDA Label: Inlyta
Disease/s that Drug Treats:advanced renal cell carcinoma
Indications and Usage:16 INLYTA is a kinase inhibitor indicated for the treatment of advancedrenal cell carcinoma after failure of one prior systemic therapy. (1)
DrugBank Targets:14 1. Vascular endothelial growth factor receptor 1;2. Vascular endothelial growth factor receptor 2;3. Vascular endothelial growth factor receptor 3
Mechanism of Action:16 
Target: receptor tyrosine kinases
Action: inhibitor
FDA: Axitinib has been shown to inhibit receptor tyrosine kinases including vascular endothelial growthfactor receptors (VEGFR)-1, VEGFR-2, and VEGFR-3 at therapeutic plasma concentrations. Thesereceptors are implicated in pathologic angiogenesis, tumor growth, and cancer progression. VEGFmediatedendothelial cell proliferation and survival were inhibited by axitinib in vitro and in mousemodels. Axitinib was shown to inhibit tumor growth and phosphorylation of VEGFR-2 in tumor xenograftmouse models.
4
Nexavar16 44 SORAFENIB TOSYLATE Bayer/Onyx December 2005
FDA Label: Nexavar
Disease/s that Drug Treats:Renal Cell Carcinoma
Indications and Usage:16 NEXAVAR is a kinase inhibitor indicated for the treatment of Unresecta ble hepatocellular carcinoma (1.1) adjust thyroid repla cement therapy in patients with thyroid ca ncer. (5.12) Advanced renal cell carcinoma (1.2) Locally recurrent or meta static, progressive, differentiated thyroid carcinoma refractory to ra dioactive iodine treatment (1.3)
DrugBank Targets:14 1. Serine/threonine-protein kinase B-raf;2. RAF proto-oncogene serine/threonine-protein kinase;3. Vascular endothelial growth factor receptor 3;4. Vascular endothelial growth factor receptor 2;5. Receptor-type tyrosine-protein kinase FLT3;6. Platelet-derived growth factor receptor beta;7. Mast/stem cell growth factor receptor Kit;8. Fibroblast growth factor receptor 1;9. Proto-oncogene tyrosine-protein kinase receptor Ret;10. Vascular endothelial growth factor receptor 1
Mechanism of Action:16 
Target: c-CRAF, BRAF and mutant BRAF, KIT, FLT- 3, RET, RET/PTC, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR-ß
Action: inhibitor
FDA: Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro.Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surfacekinases (KIT, FLT- 3, RET, RET/PTC, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR-ß). Several of thesekinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis. Sorafenib inhibited tumorgrowth of HCC, RCC, and DTC human tumor xenografts in immunocompromised mice. Reductions in tumorangiogenesis were seen in models of HCC and RCC upon sorafenib treatment, and increases in tumor apoptosiswer e obser ved in models of HCC, RCC, and DTC.
5
Proleukin16 44 ALDESLEUKIN Chiron January 1998
FDA Label: Proleukin
Disease/s that Drug Treats:Metastatic melanoma
Indications and Usage:16 Proleukin® (aldesleukin) is indicated for the treatment of adults with metastatic renal cellcarcinoma (metastatic RCC).Proleukin is indicated for the treatment of adults with metastatic melanoma.Careful patient selection is mandatory prior to the administration of Proleukin. See“CONTRAINDICATIONS”, “WARNINGS” and “PRECAUTIONS” sections regarding patientscreening, including recommended cardiac and pulmonary function tests and laboratorytests.Evaluation of clinical studies to date reveals that patients with more favorable ECOGperformance status (ECOG PS 0) at treatment initiation respond better to Proleukin, with ahigher response rate and lower toxicity (See “CLINICAL PHARMACOLOGY” section,“CLINICAL STUDIES” section and “ADVERSE REACTIONS” section). Therefore, selectionof patients for treatment should include assessment of performance status.Experience in patients with ECOG PS >1 is extremely limited.
DrugBank Targets:14 1. Interleukin-2 receptor subunit beta;2. Interleukin-2 receptor subunit alpha;3. Cytokine receptor common subunit gamma
Mechanism of Action:16 
Target: human cells
Action: enhancer of immune response and strnaght ( lymphocytemitogenesis, growth of human interleukin-2 dependent cell lines, lymphocyte cytotoxicity, induction of killer cell activity and interferon-gamma production)
FDA: Proleukin® (aldesleukin) has been shown to possess the biological activities of human nativeinterleukin-2.1,2 In vitro studies performed on human cell lines demonstrate theimmunoregulatory properties of Proleukin, including: a) enhancement of lymphocytemitogenesis and stimulation of long-term growth of human interleukin-2 dependent cell lines;b) enhancement of lymphocyte cytotoxicity; c) induction of killer cell (lymphokine-activated(LAK) and natural (NK)) activity; and d) induction of interferon-gamma production.The in vivo administration of Proleukin in animals and humans produces multipleimmunological effects in a dose dependent manner. These effects include activation ofcellular immunity with profound lymphocytosis, eosinophilia, and thrombocytopenia, and theproduction of cytokines including tumor necrosis factor, IL-1 and gamma interferon. 3 In vivoexperiments in murine tumor models have shown inhibition of tumor growth.4 The exactmechanism by which Proleukin mediates its antitumor activity in animals and humans isunknown.
6
Sutent16 44 SUNITINIB MALATE Pfizer May 2011/ January 2006
FDA Label: Sutent
Disease/s that Drug Treats:pancreatic neuroendocrine tumors/ Kidney Cancer/Gastrointestinal Stromal Tumors
Indications and Usage:16 SUTENT is a kinase inhibitor indicated for the treatment of: Gastrointestinal stromal tumor (GIST) after disease progression on orintolerance to imatinib mesylate. (1.1) Advanced renal cell carcinoma (RCC). (1.2) Progressive, well-differentiated pancreatic neuroendocrine tumors(pNET) in patients with unresectable locally advanced or metastaticdisease. (1.3)
DrugBank Targets:14 1. Platelet-derived growth factor receptor beta;2. Vascular endothelial growth factor receptor 1;3. Mast/stem cell growth factor receptor Kit;4. Vascular endothelial growth factor receptor 2;5. Vascular endothelial growth factor receptor 3;6. Receptor-type tyrosine-protein kinase FLT3;7. Macrophage colony-stimulating factor 1 receptor;8. Platelet-derived growth factor receptor alpha
Mechanism of Action:16 
Target: variety of kinases, platelet-derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factorreceptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3(FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factorreceptor (RET)
Action: inhibitor
FDA: Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which areimplicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib wasevaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitorof platelet-derived growth factor receptors (PDGFRα and PDGFRβ), vascular endothelial growth factorreceptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3(FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factorreceptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical andcellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primarymetabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays.Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFR, VEGFR2, KIT) in tumor xenograftsexpressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/orinhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibitgrowth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibitPDGFR- and VEGFR2-dependent tumor angiogenesis in vivo.
7
Torisel16 44 TEMSIROLIMUS Wyeth May 2007
FDA Label: Torisel
Disease/s that Drug Treats:renal cell carcinoma
Indications and Usage:16 TORISEL® is a kinase inhibitor indicated for the treatment of advanced renalcell carcinoma. (1)
DrugBank Targets:14 1. Serine/threonine-protein kinase mTOR
Mechanism of Action:16 
Target: mTOR
Action: inhibitor
FDA: Temsirolimus is an inhibitor of mTOR (mammalian target of rapamycin). Temsirolimus binds toan intracellular protein (FKBP-12), and the protein-drug complex inhibits the activity of mTORthat controls cell division. Inhibition of mTOR activity resulted in a G1 growth arrest in treatedtumor cells. When mTOR was inhibited, its ability to phosphorylate p70S6k and S6 ribosomalprotein, which are downstream of mTOR in the PI3 kinase/AKT pathway was blocked. Inin vitro studies using renal cell carcinoma cell lines, temsirolimus inhibited the activity of mTORand resulted in reduced levels of the hypoxia-inducible factors HIF-1 and HIF-2 alpha, and thevascular endothelial growth factor.
8
Votrient16 44 PAZOPANIB HYDROCHLORIDE GlaxoSmithKline April 2012/ October of 2009
FDA Label: Votrient
Disease/s that Drug Treats:soft tissue sarcoma/ renal cell carcinoma
Indications and Usage:16 VOTRIENT is a kinase inhibitor indicated for the treatment of patients with: advanced renal cell carcinoma. (1) advanced soft tissue sarcoma who have received prior chemotherapy. (1)Limitation of Use: The efficacy of VOTRIENT for the treatment of patientswith adipocytic soft tissue sarcoma or gastrointestinal stromal tu mors has notbeen demonstrated.
DrugBank Targets:14 1. Vascular endothelial growth factor receptor 1;2. Vascular endothelial growth factor receptor 2;3. Vascular endothelial growth factor receptor 3;4. Platelet-derived growth factor receptor alpha;5. Platelet-derived growth factor receptor beta;6. Mast/stem cell growth factor receptor Kit;7. Fibroblast growth factor receptor 3;8. Tyrosine-protein kinase ITK/TSK;9. Fibroblast growth factor 1;10. SH2B adapter protein 3
Mechanism of Action:16 
Target: vascular epidermal growth factor receptor (VEGFR) tyrosine kinase
Action: inhibitor
FDA: Pazopanib is a multi-tyrosine kinase inhibitor of vascular endothelial growth factorreceptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-αand -β, fibroblast growth factor receptor (FGFR)-1 and -3, cytokine receptor (Kit), interleukin-2receptor-inducible T-cell kinase (Itk), leukocyte-specific protein tyrosine kinase (Lck), andtransmembrane glycoprotein receptor tyrosine kinase (c-Fms). In vitro, pazopanib inhibitedligand-induced autophosphorylation of VEGFR-2, Kit, and PDGFR-β receptors. In vivo,pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation in mouse lungs, angiogenesis ina mouse model, and the growth of some human tumor xenografts in mice.

Drugs for Renal Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 578)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Sunitinibapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1510341031-54-7, 557795-19-45329102
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
 
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU-010398
SU-011248 L-malate salt
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
SU010398
SU011248
SU011248 L-malate salt
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (free base)
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
sunitinib
sunitinibum
2
AldesleukinapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 140585898-30-2, 110942-02-4
Synonyms:
125-L-serine-2-133-interleukin 2 (human reduced)
 
Interleukin-2 aldesleukin
Interleukin-2(2-133),125-ser
Recombinant interleukin-2 human
3
Sirolimusapproved, investigationalPhase 4, Phase 2, Phase 3, Phase 1194053123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
4
Miconazoleapproved, investigational, vet_approvedPhase 4, Phase 2, Phase 3, Phase 1370622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
5
EverolimusapprovedPhase 4, Phase 2, Phase 3, Phase 11940159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
6
Epinephrineapproved, vet_approvedPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 198551-43-45816
Synonyms:
(-)-(R)-Epinephrine
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-dihydroxy-a-[(methylamino)methyl]-Benzyl alcohol
(-)-3,4-dihydroxy-alpha-[(methylamino)methyl]-Benzyl alcohol
(-)-Adrenalin
(-)-Adrenaline
(-)-Epinephrine
(-)-R-Epinephrine
(R)-(-)-Adnephrine
(R)-(-)-Adrenaline
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-(−)-adrenaline
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-4-[1-hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
(R)-Adrenaline
(R)-Epinephrine
(−)-adrenaline
02252_FLUKA
1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
1-Adrenalin
1-Epinephrine
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-(1-hydroxy-2-methylamino-ethyl)benzene-1,2-diol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol
51-43-4
51-43-4 (FREE BASE)
51028-73-0
A0173
AC-13188
AC1L1L7B
ADR ADRENALINE
ADROP
AI3-19015
Adnephrine
Adrenal
Adrenalin
Adrenalin (TN)
Adrenalin in Oil
Adrenalin-Medihaler
Adrenalina
Adrenalina [DCIT]
Adrenaline
Adrenaline (JP15)
Adrenaline/Epinephrine
Adrenalinum
Adrenamine
Adrenan
Adrenapax
Adrenasol
Adrenatrate
Adrenine
Adrenodis
Adrenohorma
Adrenosan
Adrenutol
Adrin
Adrine
Ana-Guard
Ana-Kit
Antiasthmatique
Asmatane Mist
Asthma meter mist
Asthma-nefrin
Asthmahaler Mist
Asthmanefrin
Astmahalin
Astminhal
BIDD:GT0119
Balmadren
Bernarenin
Biorenine
Bosmin
Brevirenin
Bronkaid
Bronkaid Mist
Bronkaid Suspension Mist
Bupivacaine Hcl and Epinephrine
C00788
CCRIS 4812
CHEBI:28918
CHEMBL679
CID5816
Chelafrin
Citanest Forte
Corisol
D-Epifrin
D-Epinephrine
D00095
DB00668
Drenamist
Dylephrin
Dyspne-Inhal
E4250_SIGMA
EINECS 200-098-7
EPI E Z PEN JR
EPIPEN E Z PEN
EPIPEN JR
Epi EZ Pen Jr
Epifrin
Epiglaufrin
Epinefrin
Epinefrin [Czech]
Epinefrina
Epinefrina [INN-Spanish]
Epinephran
Epinephrin
Epinephrine
Epinephrine (USP)
Epinephrine (USP/INN)
Epinephrine [USAN:INN:JAN]
Epinephrine hydrochloride
Epinephrinum
Epinephrinum [INN-Latin]
Epipen
Epipen (TN)
Epipen Auto-Injector
Epipen EZ Pen
Epipen Jr.
Epipen Jr. Auto-Injector
Epirenamine
Epirenan
Epirenin
Epitrate
Eppy
Esphygmogenina
Exadrin
 
Glaucon
Glaucosan
Glauposine
Glycirenan
HSCI1_000215
HSDB 4289
Haemostasin
Haemostatin
Hektalin
Hemisine
Hemostasin
Hemostatin
Hypernephrin
Hyporenin
IOP
Intranefrin
Iontocaine
Isoptoepinal
Kidoline
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-Adrenaline
L-Adrenaline Base
L-Epinehphrine
L-Epinephrine
L-Epirenamine
L-Methylaminoethanolcatechol
L-epinephrine
LS-156
Levo-Methylaminoethanolcatechol
Levoadrenaline
Levoepinephrine
Levorenen
Levorenin
Levorenine
Levoreninum
Lopac-E-4642
Lyodrin
Lyophrin
Medihaler-Epi
Metanephrin
Methylaminoethanolcatechol
Methylarterenol
Micronefrin
Micronephrine
MolPort-002-051-368
Mucidrina
Myosthenine
Mytrate
NCGC00015417-01
NCGC00142615-01
NCGC00142615-03
NCGC00142615-04
NCGC00142615-05
NCGC00142615-06
NCGC00142615-07
NSC 62786
NSC62786
Nephridine
Nieraline
PDSP1_001120
PDSP2_001104
Paranephrin
Primatene
Primatene Mist
R-(-)-Epinephrine
R-Adrenaline
RCRA waste no. P042
Racemic Epinephrine
Racepinephrine
Rcra waste number P042
Renagladin
Renaglandin
Renaglandulin
Renaleptine
Renalina
Renoform
Renostypricin
Renostypticin
Renostyptin
SMP1_000227
ST069368
SUS-PHRINE SULFITE-FREE
Scurenaline
Septocaine
Simplene
Sindrenina
Soladren
Sphygmogenin
Stryptirenal
Styptirenal
Supracapsulin
Supradin
Supranefran
Supranephrane
Supranephrine
Supranol
Suprarenaline
Suprarenin
Suprel
Surenine
Surrenine
Sus-Phrine
Sus-phrine
Susphrine
Sympathin I
Takamina
Takamine
Tokamina
Tonogen
Twinject
Twinject 0.15
Twinject 0.3
Twinject 0.30
UNII-YKH834O4BH
Vaponefrin
Vasoconstrictine
Vasoconstrictor
Vasodrine
Vasoton
Vasotonin
adrenaline
bmse000316
d-Adrenaline
epinephrine
l-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
l-Adrenalin
l-Adrenaline
l-Epinephine
l-Epinephrine (synthetic)
l-Epirenamine
l-Methylaminoethanolcatechol
levoepinephrine
nchembio747-comp9
7
Sorafenibapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1700284461-73-0216239, 406563
Synonyms:
284461-73-0
4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide
4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE
AB1004622
AC-1674
AC1L50CF
BAX
BAY 43-9006
BAY 43-9006 (free base)
BAY 43-9006 tosylate salt
BAY 439006
BAY 54-9085 (tosylate salt)
BAY-43-0006
BAY-43-9006
BAY-54-9085
BAY43-9006
BRD-K23984367-001-01-8
Bio-0100
CHEBI:47228
CHEBI:50924
CHEMBL1336
CID216239
 
D08524
DB00398
DB07438
EN002709
I06-0856
K00597a
Kinome_766
LS-186067
LS-187021
LS-187788
MolPort-003-850-270
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea
N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
NCGC00167488-01
NSC-724772
NSC747971
Nexavar
STK627350
Sorafenib
Sorafenib (INN)
Sorafenib [INN]
Sorafenib tosylate
Sorafenibum
UNII-9ZOQ3TZI87
ZINC01493878
nchembio.117-comp17
sorafenib
sorafenibum
8
Mycophenolic acidapprovedPhase 4, Phase 2, Phase 195224280-93-1446541
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
 
Melbex
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolsäure
Myfortic
9
Axitinibapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1109319460-85-06450551
Synonyms:
319460-85-0
790713-39-2
AC-1539
AC1O51X3
AG 013736
AG-013736
AG-013736, Axitinib
AG-13736
AG013736
Axitinib
C503983
CID6450551
 
EC-000.2322
I14-1971
INLYTA
Inlyta
MolPort-006-392-413
N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide
N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
S1005_Selleck
ST51054130
UNII-C9LVQ0YUXG
ZINC03816287
axitinib
axitinibum
10
Tacrolimusapproved, investigationalPhase 4, Phase 3, Phase 21102104987-11-3445643, 439492
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
AKOS005145901
Advagraf
Ambap104987-11-3
Ambap5429
Anhydrous tacrolimus
BCBcMAP01_000194
BRD-K35452788-001-02-1
BSPBio-001279
BSPBio_001279
Bio-0921
Bio2_000470
Bio2_000950
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
CPD-10016
CPD000466356
D08556
DB00864
DivK1c_001040
FK 506
FK-506
FK5
FK506
FR 900506
FR-900506
 
FR900506
FT-0082660
Fk-506
Fujimycin
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
IDI1_001040
IDI1_002225
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus (anhydrous)
Tacrolimus anhydrous
Tacrolimus hydrate
Tacrolimus, anhydrous
Tsukubaenolide
UNII-Y5L2157C4J
nchembio.2007.23-comp2
tacrolimus
tacrolimus hydrate
11
Cyclosporineapproved, investigational, vet_approvedPhase 4, Phase 2, Phase 192279217-60-0, 59865-13-35284373, 6435893
Synonyms:
1c5f
1cyn
30024_FLUKA
30024_SIGMA
59865-13-3
79217-60-0
AC1L1EQW
AC1NQXJE
AC1NR4C4
AC1NUQK3
AC1NUZNC
AC1O5KOG
AC1Q2UDG
Ambap59865-13-3
Ambotz59865-13-3
Antibiotic S 7481F1
BMT-ABA-SAR-MLE-VAL-MLE-ALA-ALA-MLE-MLE-MVA
BMT-ABA-SAR-MLE-VAL-MLE-ALA-DAL-MLE-MLE-MVA
BPBio1_000496
BRD-A64290322-001-01-6
BRD-A69815203-001-04-3
BRD-K13533483-001-03-0
BSPBio_000450
BSPBio_001596
BSPBio_003186
C 3662
C05086
C1832_SIGMA
C3662_SIGMA
C62H111N11O12
CB-01-09 MMX
CHEBI:106343
CHEBI:328305
CHEBI:4031
CHEMBL160
CHEMBL386389
CHEMBL532318
CID2909
CID5280754
CID5284373
CID5458585
CID5497195
CID6435893
CSA
CYCLOSPORIN A (SEE ALSO TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A))
CYCLOSPORIN A, USP
Ciclosporin
Ciclosporin (JP15)
Ciclosporina
Ciclosporine
Ciclosporinum
Cipol N
Cipol-N
Consupren
Consupren S
CsA
CsA & IFN.alpha.
CyA
Cyclokat
Cyclosporin
Cyclosporin A
Cyclosporin A & IFN.alpha.
Cyclosporin A Implant
Cyclosporin A, Tolypocladium inflatum
Cyclosporine (USP)
Cyclosporine A
Cyclosporine [USAN]
D00184
DE-076
DivK1c_000871
EU-0100242
Equoral
GNF-Pf-2808
Gengraf
Gengraf (TN)
HMS1569G12
HMS1791P18
HMS1921L20
HMS1989P18
HMS2089A09
HMS2092F06
HMS502L13
Helv Chim Acta 60: 1568 (1977)
 
I06-0379
I06-0966
IDI1_000871
KBio1_000871
KBio2_000780
KBio2_003348
KBio2_005916
KBio3_002686
KBioGR_001898
KBioSS_000780
LMPK14000003
LS-257
LS-58836
Lopac0_000242
MLS000028376
MLS001333756
MLS002153454
MLS002207033
Mitogard
Modusik-A
MolPort-000-760-988
MolPort-005-934-008
MolPort-006-705-994
NCGC00093704-01
NCGC00093704-02
NCGC00093704-03
NCGC00093704-04
NCGC00093704-05
NCGC00093704-06
NCGC00093704-07
NCGC00093704-08
NCGC00164258-01
NCGC00164258-02
NINDS_000871
NSC290193
Neoplanta
Neoral
Neoral (TN)
NeuroSTAT
Nova-22007
OL 27-400
OL-27400
OLO-400
Papilock
Prestwick2_000435
Prestwick3_000435
Prestwick_731
Pulminiq
Ramihyphin A
Restasis
Restasis (TN)
S-Neoral
S1514_Selleck
SDZ-OXL 400
SMR000058578
SPBio_001467
SPECTRUM1502202
ST-603
Sandimmun
Sandimmun Neoral
Sandimmune
Sandimmune (TN)
Sandimmune, Gengraf, Restasis, Atopica, Sangcya, Cyclosporine
Sang-2000
Sang-35
SangCyA
Sangcya
Sigmasporin
Sigmasporin Microoral
Spectrum2_001484
Spectrum3_001593
Spectrum4_001279
Spectrum5_001628
Spectrum_000300
TRANSGENIC MODEL EVALUATION (CYCLOSPORIN A)
Vekacia
Zyclorin
cyclophorine
cyclosporin A
cyclosporine
from Tolypocladium inflatum (Trichoderma polysporin)
nchembio.184-comp6
nchembio.301-comp5
nchembio.342-comp1
12
Bevacizumabapproved, investigationalPhase 4, Phase 3, Phase 1, Phase 2, Early Phase 12020216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
13
Mycophenolate mofetilapproved, investigationalPhase 4, Phase 2, Phase 1952128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil
14
GemcitabineapprovedPhase 4, Phase 3, Phase 2, Phase 1201895058-81-460750
Synonyms:
103882-84-4
122111-03-9
2',2'-DiF-dC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-.beta.-D-2',2'-difluorocytidine
2'-Deoxy-2',2'-difluorocytidine
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one
4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
95058-81-4
AB1004842
AC1L1TUQ
C07650
CCRIS 8984
CHEBI:175901
CHEMBL888
CID60750
Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine
D02368
DB00441
DDFC
DFDC
DFdC
DFdCyd
Folfugem
GEO
Gamcitabine
GemLip
Gemcel
 
Gemcin
Gemcitabin
Gemcitabina
Gemcitabina [INN-Spanish]
Gemcitabine
Gemcitabine (USAN/INN)
Gemcitabine HCl
Gemcitabine hydrochloride
Gemcitabine stereoisomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
Gemzar (hydrochloride)
HMS2089P10
HSDB 7567
Inno-D07001
LS-59139
LY 188011
LY-188011
LY188011
NCGC00168784-01
NChemBio.2007.10-comp25
NSC 613327
NSC613327
TL8005979
UNII-B76N6SBZ8R
ZINC18279854
Zefei
gemcitabine
nchembio.573-comp7
nchembio.90-comp2
15
CisplatinapprovedPhase 4, Phase 3, Phase 2, Phase 1277015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
16
Fentanylapproved, illicit, investigational, vet_approvedPhase 4, Phase 2, Phase 3821437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
1-phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl CII
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
 
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
fentanyl
17
NicotineapprovedPhase 4110354-11-5942, 89594
Synonyms:
(−
(+)-Nicotine
(-)-3-(1-Methyl-2-pyrrolidyl)pyridine
(-)-3-(N-Methylpyrrolidino)pyridine
(-)-Nicotine
(-)-Nicotine solution
(2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine
(R)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(R,S)-Nicotine
(S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE
(S)-(-)-Nicotine
(S)-(−)-nicotine
(S)-3-(1-methylpyrrolidin-2-yl)pyridine
(S)-3-(N-methylpyrrolidin-2-yl)pyridine
(S)-Nicotine
(−)-nicotine
)-1-Methyl-2-(3-pyridyl)pyrrolidine
)-Nicotine
)-Nicotine solution
1-Methyl-2-(3-pyridal)-Pyrrolidine
1-Methyl-2-(3-pyridal)-pyrrolidene
1-Methyl-2-(3-pyridiyl)pyrrolidine
1-Methyl-2-(3-pyridyl)pyrrolidine
1uw6
2'-beta-H-Nicotine
3-(1-Methyl-2-pyrollidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)-Pyridine
3-(1-Methyl-2-pyrrolidinyl)pyridine
3-(1-Methylpyrrolidin-2-yl)pyridine
3-(2-(N-methylpyrrolidinyl))pyridine
3-(N-Methylpyrollidino)pyridine
3-(N-Methylpyrrolidino)pyridine
3-(N-methylpyrollidino)pyridine
3-N-Methylpyrrolidine
3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
36733_FLUKA
36733_RIEDEL
434F7990-3240-4A43-ACEC-E6CC1E495FA0
46343_FLUKA
46343_RIEDEL
54-11-5
AC1L3I79
AC1Q3ZOC
AI3-03424
BB_NC-0777
BIDD:GT0599
BRD-K05395900-322-02-1
Black Leaf
Black Leaf 40
C00745
CCRIS 1637
CHEBI:17688
CHEMBL3
CID89594
CPD000059074
Campbell's Nico-Soap
Caswell No. 597
Commit
D-Nicotine
D03365
DL-tetrahydronicotyrine
Destruxol
Destruxol Orchid Spray
EINECS 200-193-3
ENT 3,424
EPA Pesticide Chemical Code 056702
Emo-Nik
Flux Maag
Fumeto bac
Fumetobac
HSDB 1107
Habitrol
Habitrol (TN)
L(-)-nicotine
L(−)-nicotine
L-3-(1-Methyl-2-pyrrolidyl)pyridine
 
L-Nicotine
LS-202
MLS001055457
MLS001335905
Mach-Nic
Methyl-2-pyrrolidinyl)pyridine
Micotine
MolPort-000-744-731
N3876_SIGMA
N5511_FLUKA
N5511_SIGMA
NCGC00090693-01
NCGC00090693-02
NCGC00090693-03
NCGC00090693-04
NCGC00090693-05
NCGC00090693-06
NCGC00090693-07
NCT
NICOTINE AND SALTS
NSC 5065
NSC97238
Niagara P.A. Dust
Nic-Sal
Nico-Dust
Nico-Fume
Nicocide
Nicoderm
Nicoderm Cq
Nicoderm Patch
Nicorette
Nicorette Plus
Nicotin
Nicotina
Nicotina [Italian]
Nicotine
Nicotine (USP)
Nicotine (compounds related to)
Nicotine Alkaloid
Nicotine Patch
Nicotine Polacrilex
Nicotine [BSI:ISO]
Nicotine [UN1654]
Nicotine [UN1654] [Poison]
Nicotine [USAN]
Nicotrol
Nicotrol Inhaler
Nicotrol Ns
Nictoine patch
Nikotin
Nikotin [German]
Nikotyna
Nikotyna [Polish]
Ortho N-4 Dust
Ortho N-5 Dust
PDSP1_000113
PDSP1_000465
PDSP2_000463
PDSP2_000555
Prostep
R)-(+)-Nicotine
RCRA waste no. P075
RCRA waste number P075
SAM002564224
SDCCGMLS-0066911.P001
SMR000059074
Tendust
Transdermal Nicotine
UN1654
a -N-Methylpyrrolidine
a-N-Methylpyrrolidine
alpha-N-Methylpyrrolidine
beta-Pyridyl-alpha-N-methyl pyrrolidine
beta-Pyridyl-alpha-N-methylpyrrolidine
bmse000105
delta-Nicotine
nicotine
nicotine replacement patch
18
Bupivacaineapproved, investigationalPhase 4, Phase 2, Phase 312332180-92-9, 38396-39-32474
Synonyms:
( inverted exclamation markA)-bupivacaine
(+-)-Bupivacaine
(1)-1-Butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
(RS)-bupivacaine
(±)-bupivacaine
1-Butyl-2',6'-pipecoloxylidide
1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide
1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
15233-43-9
2180-92-9
38396-39-3
AB00053674
AC-2096
AC1L1DRE
AC1Q5LX4
AH 250
AKOS001637202
AR-1A0242
Anekain
BPBio1_000298
BRD-A01636364-003-05-2
BSPBio_000270
BSPBio_002607
Bio-0886
Bloqueina
Bucaine
Bucaine (TN)
Bupivacaina
Bupivacaina [INN-Spanish]
Bupivacaine (INN)
Bupivacaine Carbonate
Bupivacaine HCL
Bupivacaine HCL KIT
Bupivacaine Monohydrochloride, Monohydrate
Bupivacaine [INN:BAN]
Bupivacainum
Bupivacainum [INN-Latin]
Bupivan
C07529
C18H28N2O
CBupivacaine
CHEBI:3215
CHEMBL1098
CID2474
Carbostesin
D07552
DB00297
DL-Bupivacaine
DUR-843
 
DepoBupivacaine
DivK1c_000758
EINECS 218-553-3
EINECS 253-911-2
HMS2090F12
IDI1_000758
KBio1_000758
KBio2_002004
KBio2_004572
KBio2_007140
KBio3_001827
KBioGR_001516
KBioSS_002004
KST-1A4609
L000695
LAC-43
LS-109841
LS-2222
MLS001361336
Marcaina
Marcaine
Marcaine HCL
Marcaine Spinal
MolPort-004-955-820
NCGC00178579-01
NCGC00178579-02
NINDS_000758
NSC119660
Prestwick0_000305
Prestwick1_000305
Prestwick2_000305
Prestwick3_000305
SMR000058218
SPBio_001558
SPBio_002489
Sensorcaine
Sensorcaine-MPF
Sensorcaine-MPF Spinal
Spectrum2_001589
Spectrum3_000974
Spectrum4_001098
Spectrum5_001483
Spectrum_001524
Transdur-Bupivacaine
UNII-Y8335394RO
Win 11318
Win 11318 HCl
bupivacaine
cBupivacaine
dl-1-Butyl-2',6'-pipecoloxylidide
racemic bupivacaine
19
nivolumabapprovedPhase 4, Phase 3, Phase 1, Phase 2, Early Phase 1424946414-94-4
Synonyms:
BMS-936558
 
MDX-1106
ONO-4538
nivolumab
20
RibavirinapprovedPhase 4, Phase 3100336791-04-537542
Synonyms:
1-.beta.-D-Ribofuranosyl-1,2,4-triazolo-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide
1-beta-D-ribofuranosyl-1-H-1,2,4-triazole-3-carboxamide
36791-04-5
437710-49-1
66510-90-5
AA-504/07617051
AB00430481
AC1L1XXZ
AC1Q1IDC
AC1Q4ZGS
AKOS001715163
BB_NC-0567
BPBio1_001195
BRN 0892462
BSPBio_001085
BSPBio_003352
C-Virin
CHEMBL1643
CID37542
Copegus
Copegus (TN)
Cotronak
D00423
DB00811
DRG-0028
DivK1c_000782
Drug: Ribavirin
EU-0101063
FT-0082885
HMS2090L15
HMS2094O09
HMS502H04
HSDB 6513
ICN-1229
IDI1_000782
KBio1_000782
KBio2_002328
KBio2_004896
KBio2_007464
KBio3_002854
KBioGR_001804
KBioSS_002331
KS-1104
LS-1241
Lopac0_001063
MLS000028486
MLS002222317
MolPort-002-507-104
MolPort-002-885-856
NCGC00090726-01
NCGC00090726-03
NCGC00090726-04
NCGC00090726-05
NCGC00090726-06
NCGC00090726-07
NINDS_000782
NSC 163039
 
NSC163039
Prestwick3_000993
R 9644
R-964
R9644_SIGMA
RBV
RG-964
RIBAV
RTC
RTCA
RTP
Ravanex
Rebetol
Rebetol (TN)
Rebetron
Rebretron
Ribacine
Ribamide
Ribamidil
Ribamidyl
Ribasphere
Ribasphere (TN)
Ribav
Ribavirin
Ribavirin (JAN/USP/INN)
Ribavirin Capsules
Ribavirin Triphosphate
Ribavirin [USAN:INN]
Ribavirin-TP
Ribavirina
Ribavirina [INN-Spanish]
Ribavirine
Ribavirine [INN-French]
Ribavirinum
Ribavirinum [INN-Latin]
Ribovirin
Ro 20-9963/000
Ro-20-9963
S2504_Selleck
SCH 18908
SMP1_000261
SMR000058315
SPECTRUM1503938
SR-01000076112-3
Spectrum3_001876
Spectrum4_001252
Spectrum5_002075
Spectrum_001826
Tribavirin
UNII-49717AWG6K
Varazid
Vilona
Viramid
Viramide
Virazid
Virazide
Virazole
Virazole (Ribavirin) Inhalation Solution
Virazole (TN)
Virazole 5'-triphosphate
ZINC01035331
ribavirin
21
Midazolamapproved, illicitPhase 4, Phase 172359467-70-84192
Synonyms:
4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluoro-phenyl)-1-methyl-, (Z)-2-butenedioate
59467-70-8
8-Chlor-6-(2-fluorphenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepin
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5a][1,4]benzodiazepine hydrochloride
8-Chloro-6-(O-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]-benzodiazepine
8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepine
AC-18749
AC1L1HMA
BIDD:GT0647
BRN 0625572
Buccolam
C07524
C18H13ClFN3
CHEMBL655
CID4192
D00550
DB00683
DEA No. 2884
Dazolam
Dea No. 2884
 
Dormicum
Dormicum (TN)
EINECS 261-774-5
LS-77780
Midanium
Midazolam
Midazolam (JAN/INN)
Midazolam Base
Midazolam Hcl
Midazolam [INN:BAN:JAN]
Midazolamum
Midazolamum [INN-Latin]
Midosed
MolPort-003-849-219
NCGC00168254-01
Ro 21-3981
TL8003787
UC429_SIGMA
UNII-R60L0SM5BC
Versed
ZINC00001732
midazolam
nchembio747-comp32
22
Peginterferon alfa-2aapproved, investigationalPhase 4, Phase 2, Phase 3, Phase 1565198153-51-45360545
Synonyms:
198153-51-4
D02747
Pegasys
Pegasys (TN)
 
Peginterferon alfa-2a
Peginterferon alfa-2a (USAN/INN)
Peginterferon alfa-2a (genetical recombination)
Peginterferon alfa-2a (genetical recombination) (JAN)
Pegylated interferon alfa-2a
Pegylated interferon alpha2a
23
Zoledronic acidapprovedPhase 4, Phase 3, Phase 1, Phase 2294118072-93-868740
Synonyms:
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
(1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
(1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid
(1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate
(1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
118072-93-8
2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid
2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
AC-1092
AC1L2ACJ
AC1Q6RN3
AKOS005145739
Aclasta
Anhydrous Zoledronic Acid
BIDD:GT0292
BIDD:PXR0134
Bio-0112
Bisphosphonate 3
C088658
CGP 42'446
CGP 42446
CGP 42446A
CGP-42'446
CGP-42446
CHEBI:46557
CHEMBL924
CID68740
D08689
DB00399
 
FT-0082657
HMS2089O09
I06-0710
KS-1132
LS-181815
MolPort-002-885-874
MolPort-003-850-890
NCGC00159521-02
NCGC00159521-03
NSC721517
Novartis brand of zoledronic acid
Reclast
Reclast (TN)
S00092
S1314_Selleck
UNII-70HZ18PH24
ZOL
Zol
Zoledronate
Zoledronic Acid Anhydrous
Zoledronic Acid, Anhydrous
Zoledronic acid
Zoledronic acid (INN)
Zoledronic acid [USAN:INN]
Zometa
Zometa (Novartis)
Zometa (TN)
Zometa Concentrate
Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid
[1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid)
24
Dexmedetomidineapproved, vet_approvedPhase 459276631-46-4, 113775-47-668602, 5311068, 56032
Synonyms:
(+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole
(+)-4-((S)-alpha,2,3-trimethylbenzyl)imidazole
(+)-medetomidine
(S)-medetomidine
113775-47-6
4-[(1S)-1-(2,3-Dimethylphenyl)ethyl]-1H-imidazole
4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
AC1NSJXT
C07450
CHEBI:4466
CHEMBL778
CID5311068
D00514
DEXMEDETOMIDINE
 
Dexdor (T)
Dexmedetomidin
Dexmedetomidina
Dexmedetomidine
Dexmedetomidine (USAN/INN)
Dexmedetomidinum
Dexmédétomidine
MPV 1440
MPV-1440
Medetomidina [Spanish]
Medetomidine
Medetomidinum [Latin]
NCGC00025347-01
PRECEDEX
Precedex (TN)
Tocris-2023
ZINC04632106
25
AzathioprineapprovedPhase 4177446-86-62265
Synonyms:
446-86-6
55774-33-9 (hydrochloride salt)
6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine
6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine
6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]
6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine
6-(3-Methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-7H-purine
6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine
6-(Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(Methyl-p-nitro-5-imidazolyl)thiopurine
6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine
6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine
6-[(1-Methyl-4-nitroimidazol-5-yl)- thio] purine
6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-Purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine
A 4638
A2593_SIAL
A4638_SIAL
A4638_SIGMA
AB00443544
AB00443544-03
AC-4230
AC1L1DAL
AC1Q3Z1F
AI-981/34845012
AI3-50290
Azamun
Azamun [Czech]
Azanin
Azasan
Azasan (TN)
Azasan, Imuran, Azamun, BW-57-322, NSC-39084, Azathioprine
Azathioprin
Azathioprine (JP15/USP/INN)
Azathioprine Sodium
Azathioprine [USAN:INN:BAN:JAN]
Azathioprine sodium
Azathioprinum
Azathioprinum [INN-Latin]
Azathiopurine
Azatioprin
Azatioprina
Azatioprina [INN-Spanish]
Azothioprine
B. W. 57-322
BPBio1_000054
BRD-K32821942-001-05-6
BRD-K60324116-001-01-5
BSPBio_000048
BSPBio_001876
BW 57-322
BW 57322
BW-57-322
C06837
C9H7N7O2S
CAS-446-86-6
CBDivE_013132
CCRIS 62
CHEBI:2948
CHEMBL1542
CID2265
CPD000427366
Ccucol
ChemDiv1_002659
Cytostatics
D00238
DB00993
DivK1c_000586
EINECS 207-175-4
EU-0100027
FT-0083532
HMS1568C10
HMS1920E17
 
HMS2091K19
HMS501N08
HMS594I19
HSDB 7084
IDI1_000586
Immuran
Imuran
Imuran (TN)
Imuran (tn)
Imurek
Imurel
KBio1_000586
KBio2_000464
KBio2_002427
KBio2_003032
KBio2_004995
KBio2_005600
KBio2_007563
KBio3_001376
KBio3_002906
KBioGR_000646
KBioGR_002427
KBioSS_000464
KBioSS_002433
LS-123
Lopac-A-4638
Lopac0_000027
MLS001049307
Methylnitroimidazolylmercaptopurine
MolPort-000-745-914
MolPort-000-764-262
MolPort-003-665-485
Muran
NCGC00015060-01
NCGC00015060-02
NCGC00015060-04
NCGC00015060-12
NCGC00090836-01
NCGC00090836-02
NCGC00090836-03
NCGC00090836-04
NCGC00090836-05
NCGC00090836-06
NCGC00094593-01
NCGC00094593-02
NCGC00094593-03
NCI-C03474
NINDS_000586
NSC 39084
NSC-39084
NSC39084
Oprea1_375441
Oprea1_533384
Oprea1_633462
Prestwick0_000094
Prestwick1_000094
Prestwick2_000094
Prestwick3_000094
Prestwick_41
S1721_Selleck
SAM002589938
SDCCGMLS-0065415.P001
SMR000427366
SPBio_000255
SPBio_001987
SPECTRUM1500133
STK831906
STOCK1S-20293
STOCK1S-27186
Spectrum2_000068
Spectrum3_000308
Spectrum4_000243
Spectrum5_000848
Spectrum_000064
Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl)
UNII-MRK240IY2L
WLN: T56 BM DN FN HNJ IS- ET5N CNJ A1 DNW
ZINC04258316
[Methyl(nitroimidazolyl)mercaptopurine]
azathioprine
azatiopr in
cMAP_000046
26
Folic Acidapproved, nutraceutical, vet_approvedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1439259-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
Folsaeure
 
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
27
Nicotinamideapproved, NutraceuticalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 191998-92-0936
Synonyms:
.beta.-Pyridinecarboxamide
11032-50-1
123574-63-0
1yc5
3 Pyridinecarboxamide
3-Carbamoylpyridine
3-Pyridinecarboxamide
3-Pyridinecarboxylic acid amide
37321-14-5
47865U_SUPELCO
55600-01-6
63748-44-7
72340_FLUKA
72340_SIGMA
72347_FLUKA
78731-47-2
98-92-0
A186B02E-6C70-4E54-9739-79398D439AAA
AC-907/25014114
AC1L1ACZ
AC1Q4ZFV
AI3-02906
Acid amide
Amid kyseliny nikotinove
Amid kyseliny nikotinove [Czech]
Amide PP
Aminicotin
Amixicotyn
Amnicotin
Astra Brand of Niacinamide
Austrovit PP
B 3, Vitamin
B3, Vitamin
BB_NC-2290
Benicot
C00153
C6H6N2O
CCRIS 1901
CHEBI:17154
CHEMBL1140
CID936
CPD000058212
D00036
D009536
DB02701
DEA No. 1405
Delonin Amide
Delonin amide
Dipegyl
Dipigyl
EINECS 202-713-4
EINECS 234-265-0
Endobion
Enduramide
Factor pp
HMS2052M21
HMS2090B05
HMS2093H03
HSDB 1237
Hansamid
I02-1741
I02-2250
InChI=1/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9
Inovitan PP
Jenapharm Brand of Niacinamide
Jenapharm, Nicotinsaureamid
LS-2051
MLS000069714
Mediatric
Merck Brand of Niacinamide
MolMap_000061
MolPort-001-783-876
N0078
N0636_SIGMA
N2142_SIGMA
N3376_SIGMA
N5535_SIAL
NAM
NCGC00093354-03
NCGC00093354-04
NSC 13128
NSC13128
NSC27452
Nandervit-N
Niacevit
Niacinamide
Niacinamide (USP)
Niacinamide Astra Brand
Niacinamide Jenapharm Brand
Niacinamide Merck Brand
 
Niacinamide Pharmagenix Brand
Niacinamide [USAN]
Niacinamide, Nicotinic acid amide, Nicotinamide
Niacotinamide
Niamide
Niavit PP
Nicamide
Nicamina
Nicamindon
Nicasir
Nicobion
Nicofort
Nicogen
Nicomidol
Nicosan 2
Nicosylamide
Nicota
Nicotamide
Nicotilamide
Nicotililamido
Nicotinamid
Nicotinamida
Nicotinamida [INN-Spanish]
Nicotinamide
Nicotinamide (JP15/INN)
Nicotinamide (Niacinamide)
Nicotinamide, niacin, vitamin B3
Nicotinamide-carbonyl-14C
Nicotinamidum
Nicotinamidum [INN-Latin]
Nicotine acid amide
Nicotine amide
Nicotinic acid amide
Nicotinic amide
Nicotinsaeureamid
Nicotinsaureamid
Nicotinsaureamid Jenapharm
Nicotinsaureamid [German]
Nicotol
Nicotylamide
Nicotylamidum
Nicovel
Nicovit
Nicovitina
Nicovitol
Nicozymin
Nictoamide
Nikasan
Nikazan
Niko-tamin
Nikotinamid
Nikotinsaeureamid
Nikotinsaeureamid [German]
Niocinamide
Niozymin
PP-Faktor
Papulex
Pelmin
Pelmine
Pelonin amide
Pharmagenix Brand of Niacinamide
Propamine A
Pyridine-3-carboxylic acid amide
S1899_Selleck
SAM001246860
SGCUT00176
SMR000058212
Savacotyl
UNII-25X51I8RD4
Vi-Nicotyl
Vi-noctyl
Vitamin B
Vitamin B (VAN)
Vitamin B 3
Vitamin B3 amide
Vitamin H1
Vitamin PP
WLN: T6NJ CVZ
Witamina PP
ZINC00005878
b-Pyridinecarboxamide
beta-Pyridinecarboxamide
bmse000281
m-(Aminocarbonyl)pyridine
nchembio.154-comp4
nchembio.73-comp6
niacin - Vitamin B3
niacinamide
nicotinamide
pyridine-3-carboxamide
to_000073
vitamin PP
28
Niacinapproved, investigational, nutraceuticalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 192359-67-6938
Synonyms:
3-Carboxylpyridine
3-Carboxypyridine
3-Pyridinecarboxylate
3-Pyridinecarboxylic acid
3-Pyridylcarboxylate
3-Pyridylcarboxylic acid
3-carboxypyridine
Acide Nicotinique
Acido nicotinico
Acidum Nicotinicum
Akotin
Anti-pellagra vitamin
Apelagrin
Daskil
Efacin
Enduracin
Linic
M-Pyridinecarboxylic Acid
Niac
Niacin
Niacine
Niacor
Nicacid
Nicamin
Nicangin
 
Nico-Span
Nicobid
Nicocap
Nicodelmine
Nicolar
Niconacid
Nicosan 3
Nicotinate
Nicotinic Acid
Nicotinic acid
Nicotinipca
Nicyl
Nikotinsaeure
Nyclin
P.P. factor
PP Factor
Pellagra preventive factor
Pellagrin
Pelonin
Pyridine-beta-carboxylic acid
Slo-niacin
Vitamin B3
Wampocap
beta-Pyridinecarboxylic acid
pyridine-β-carboxylic acid
β-pyridinecarboxylic acid
29
Caffeineapproved, NutraceuticalPhase 439658-08-22519
Synonyms:
07E4FB58-FD79-4175-8E3D-05BF96954522
1,3,7-Trimethyl-2,6-dioxopurine
1,3,7-Trimethyl-3,7-dihydro-1H-purine-2,6-dione
1,3,7-Trimethylpurine-2,6-dione
1,3,7-Trimethylxanthine
1,3,7-trimethyl-2,6-dioxopurine
1,3,7-trimethylpurine-2,6-dione
1,3,7-trimethylxanthine
1-3-7-TRIMETHYLXANTHINE
1-Methyl-Theobromine
1-methyltheobromine
137X
1gfz
1l5q
1l7x
27602_FLUKA
2a3b
3,7-Dihydro-1,3,7-trimethyl-1H-purin-2,6-dion
3,7-Dihydro-1,3,7-trimethyl-1H-purine-2,6-dione
3,7-dihydro-1,3,7-trimethyl-1H-purine
5-26-13-00558 (Beilstein)
58-08-2
7-Methyl Theophylline
7-Methyltheophylline
7-methyltheophylline
71701-02-5
75035_FLUKA
95789-13-2
A.S.A. and Codeine Compound
AC-12774
AC1L1DV2
AC1Q3Z23
ACon1_000085
AI3-20154
AKOS000121334
Alert-Pep
Alert-pep
Anacin Maximum Strength
Anhydrous caffeine
Anhydrous caffeine (JP15)
Anhydrous caffeine (TN)
Anoquan
BIDD:ER0554
BIDD:GT0632
BIDD:PXR0172
BIM-0050216.0001
BRD-K02404261-001-02-7
BRD-K02404261-001-03-5
BRN 0017705
BSPBio_001921
Berlin-Chemie Brand of Caffeine
Bio-0579
Bio1_000473
Bio1_000962
Bio1_001451
Bristol-Myers Squibb Brand of Caffeine
C 0750
C07481
C0750_SIAL
C1778_SIAL
C2042
C6035_FLUKA
C6035_SIGMA
C7731_SIAL
C8960_SIAL
CCRIS 1314
CFF
CHEBI:27732
CHEMBL113
CID2519
CU-01000012617-3
Cafamil
Cafcit
Cafecon
Cafeina
Cafergot
Cafeína
Caffedrine
Caffedrine Caplets
Caffein
Caffeina
Caffeina [Italian]
Caffeine (USP)
Caffeine (natural)
Caffeine Pure
Caffeine [BAN:JAN]
Caffeine solution
Caffeine, Anhydrous
Caffeine, Monohydrate
Caffeine, Synthetic
Caffeine, anhydrous
Caffeine, synthetic
Caffeinum
Caffine
Cafipel
Caféine
Coffein
Coffein [German]
Coffeine
Coffeinum
Coffeinum N
Coffeinum Purrum
Compound 65
D002110
D00528
DB00201
DHC Plus
DHCplus
Darvon Compound
Darvon Compound-65
Dasin
Dexitac
Dexitac Stay Alert Stimulant
Dhc Plus
Diurex
DivK1c_000730
Durvitan
EINECS 200-362-1
EU-0100228
Eldiatric C
Enerjets
Ercatab
Esgic
Esgic-Plus
FEMA No. 2224
Femcet
Fioricet
Fiorinal
GlaxoSmithKline Brand of Caffeine
Guaranine
HMS1920I09
HMS2091O11
HMS502E12
HSDB 36
Hycomine
Hycomine Compound
I14-4386
 
IDI1_000730
Invagesic
Invagesic Forte
KBio1_000730
KBio2_001781
KBio2_004349
KBio2_006917
KBio3_001141
KBioGR_002325
KBioSS_001781
Keep Alert
Kofein
Kofein [Czech]
Koffein
Koffein [German]
L000155
LS-237
Lanorinal
Lopac-C-0750
Lopac0_000228
MEGxp0_001350
MLS001055341
MLS001056714
MLS001066409
Mateina
Mateína
Maximum Strength Snapback Stimulant Powders
Medigesic Plus
Merck dura Brand of Caffeine
Methyltheobromide
Methyltheobromine
Methylxanthine theophylline
Midol Maximum Strength
Migergot
Miudol
MolMap_000054
MolPort-000-730-850
Monohydrate Caffeine
Monomethyl Derivative of Theophylline
Monomethyl derivative of Theophylline
NCGC00015208-01
NCGC00015208-02
NCGC00015208-04
NCGC00015208-14
NCGC00090699-01
NCGC00090699-02
NCGC00090699-03
NCGC00090699-04
NCGC00090699-05
NCGC00090699-06
NCGC00090699-07
NCGC00090699-08
NCGC00090699-09
NCGC00168808-01
NCGC00168808-02
NCI-C02733
NCIOpen2_008255
NINDS_000730
NSC 5036
NSC5036
Natural Caffeinum
Nix Nap
No Doz
No-Doz
Nodaca
Nodoz Maximum Strength Caplets
Norgesic
Norgesic Forte
Organex
Orphengesic
Orphengesic Forte
P-A-C Analgesic Tablets
PDSP1_001016
PDSP1_001235
PDSP2_001000
PDSP2_001219
Passauer Brand of Caffeine
Pep-Back
Percoffedrinol N
Percutafeine
Phensal
Pierre Fabre Brand of Caffeine
Probes1_000150
Probes2_000128
Propoxyphene
Propoxyphene Compound 65
Propoxyphene Compound-65
Quick Pep
Quick-Pep
Refresh'n
Republic Drug Brand of Caffeine
SDCCGMLS-0064595.P001
SDCCGMLS-0064595.P002
SK 65 Compound
SK-65 Compound
SMR000326667
SPBio_001222
SPECTRUM1500155
STK177283
Seid Brand of Caffeine
Spectrum2_001261
Spectrum3_000321
Spectrum4_001782
Spectrum5_000423
Spectrum_001301
Stim
Synalgos-Dc
TNP00310
Thein
Theine
Theobromine ME
Theobromine Me
Theophylline ME
Theophylline Me
Theophylline, 7-methyl
Thompson Brand 1 of Caffeine
Thompson Brand 2 of Caffeine
Tirend
Tri-Aqua
Triad
UNII-3G6A5W338E
Ultra Pep-Back
Vivarin
W222402_ALDRICH
WLN: T56 BN DN FNVNVJ B1 F1 H1
Wake-Up
Wigraine
Xanthine, 1,3,7-trimethyl
ZINC00001084
bmse000206
cafeine
caffeine
caffenium
component of Cafergot
nchembio.243-comp7
nchembio.63-comp5
nchembio774-comp2
teina
teína
30Antirheumatic AgentsPhase 4, Phase 3, Phase 2, Phase 110956
31Neurotransmitter AgentsPhase 4, Phase 2, Phase 1, Early Phase 118340
32VitaminsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 15282
33Hypnotics and SedativesPhase 4, Phase 2, Phase 12616
34Pharmaceutical SolutionsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 18192
35Liver ExtractsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14067
36AntimetabolitesPhase 4, Phase 3, Phase 2, Phase 112054
37Interferon-alphaPhase 4, Phase 3, Phase 2, Phase 11152
38VaccinesPhase 4, Phase 3, Phase 1, Phase 26611
39Blood SubstitutesPhase 4253
40Antifungal AgentsPhase 4, Phase 2, Phase 3, Phase 13696
41Angiogenesis InhibitorsPhase 4, Phase 3, Phase 1, Phase 2, Early Phase 14257
42Plasma SubstitutesPhase 4240
43Angiogenesis Modulating AgentsPhase 4, Phase 3, Phase 1, Phase 2, Early Phase 14185
44ImmunoglobulinsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 16394
45Dermatologic AgentsPhase 4, Phase 3, Phase 2, Phase 15806
46Antimetabolites, AntineoplasticPhase 4, Phase 3, Phase 2, Phase 17361
47Vitamin B ComplexPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14337
48Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 122062
49Antibodies, MonoclonalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14039
50AntibodiesPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 16394

Interventional clinical trials:

(show top 50)    (show all 1739)
idNameStatusNCT IDPhase
1Study to the Optimal Duration of Therapy With Oral Angiogenesis InhibitorsUnknown statusNCT00777504Phase 4
2A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC)Unknown statusNCT01028729Phase 4
3Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab TreatmentCompletedNCT02056587Phase 4
4Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell CarcinomaCompletedNCT00706706Phase 4
5SUTENT® In The First Line Treatment Of Renal Cell CarcinomaCompletedNCT00460798Phase 4
6Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2.CompletedNCT01339962Phase 4
7Interleukin-2 in Treating Patients With Metastatic Kidney CancerCompletedNCT00006864Phase 4
8Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or PazopanibCompletedNCT01514448Phase 4
9Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone MetastasisCompletedNCT00172003Phase 4
10Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia MethodCompletedNCT02988219Phase 4
11Sorafenib in Elderly mRCCCompletedNCT01728948Phase 4
12Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer PatientsCompletedNCT01402089Phase 4
13Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal TumoursCompletedNCT02016391Phase 4
14Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit SmokingCompletedNCT00365508Phase 4
15Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant RecipientsCompletedNCT00129961Phase 4
16Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic FactorsRecruitingNCT02700568Phase 4
17Post Marketing Surveillance for PROSENSE™ a Cryotherapy Treatment of Renal Cell CarcinomaRecruitingNCT02399124Phase 4
18A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.RecruitingNCT01206764Phase 4
19First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell CarcinomaRecruitingNCT01521715Phase 4
20Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell CarcinomaRecruitingNCT02555748Phase 4
21Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF TherapyRecruitingNCT02570789Phase 4
22A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell CancerRecruitingNCT02982954Phase 4
23Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver CancerRecruitingNCT02081755Phase 4
24A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell CarcinomaActive, not recruitingNCT02596035Phase 4
25Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)Active, not recruitingNCT01266837Phase 4
26Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant RecipientsActive, not recruitingNCT02624349Phase 4
27Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell CarcinomaTerminatedNCT00930345Phase 4
28Phase IV Randomization to On-Going Treatment to Evaluate Sustained SorafenibTerminatedNCT00352859Phase 4
29Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE)TerminatedNCT02338570Phase 4
30Cost Effectiveness Of Sunitinib In Central America And CaribbeanTerminatedNCT01033981Phase 4
31Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino PatientsTerminatedNCT01073644Phase 4
32Hydroxyethyl Starch and Renal Function After Laparoscopic NephrectomyTerminatedNCT01486550Phase 4
33Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive ProtocolTerminatedNCT00866684Phase 4
34Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive ProtocolTerminatedNCT01797315Phase 4
35Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral LoadTerminatedNCT00977054Phase 4
36Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney CancerWithdrawnNCT01353794Phase 4
37A Post Marketing Surveillance As Required By Philippine Food And Drug AdministrationWithdrawnNCT01781442Phase 4
38Exercise for Patients With Renal Cell Cancer Receiving SunitinibUnknown statusNCT00869011Phase 3
39Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell CarcinomaUnknown statusNCT01481870Phase 3
40Chemotherapy Before and After Surgery in Treating Children With Wilm's TumorUnknown statusNCT00047138Phase 3
41Chemotherapy Plus Surgery in Treating Children at Risk of or With Stage I Wilms' TumorUnknown statusNCT00003804Phase 3
42Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis ComplexUnknown statusNCT01730209Phase 2, Phase 3
43Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder CancerUnknown statusNCT00146276Phase 3
44Clinical Study of Antiviral and Aspirin Treatment in Liver Cancer After Radical SurgeryUnknown statusNCT01936233Phase 3
45Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Advanced Cancer of the Oropharynx or HypopharynxUnknown statusNCT00003627Phase 3
46A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving ChemotherapyUnknown statusNCT01560195Phase 3
47Paclitaxel, Carboplatin, and Radiation Therapy With or Without Adjuvant Paclitaxel and Carboplatin in Treating Patients With Stage II or Stage III Unresectable Non-Small Cell Lung CancerUnknown statusNCT00077220Phase 3
48Radiation Therapy and Capecitabine With or Without Oxaliplatin in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Rectal CancerUnknown statusNCT00227747Phase 3
49Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)Unknown statusNCT01555710Phase 3
50Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal CancerUnknown statusNCT00003652Phase 3

Search NIH Clinical Center for Renal Cell Carcinoma

Inferred drug relations via UMLS68/NDF-RT46:


Cochrane evidence based reviews: carcinoma, renal cell

Genetic Tests for Renal Cell Carcinoma

About this section

Genetic tests related to Renal Cell Carcinoma:

id Genetic test Affiliating Genes
1 Renal Cell Carcinoma, Nonpapillary27
2 Renal Cell Carcinoma27 24 HNF1A

Anatomical Context for Renal Cell Carcinoma

About this section

MalaCards organs/tissues related to Renal Cell Carcinoma:

36
Kidney, Endothelial, T cells, Bone, Thyroid, Breast, Lung

Publications for Renal Cell Carcinoma

About this section

Articles related to Renal Cell Carcinoma:

(show top 50)    (show all 5233)
idTitleAuthorsYear
1
A five-long non-coding RNA signature to improve prognosis prediction of clear cell renal cell carcinoma. (28512261)
2017
2
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. (28089886)
2017
3
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma. (27939075)
2017
4
RBM10-TFE3 Renal Cell Carcinoma: A Potential Diagnostic Pitfall Due to Cryptic Intrachromosomal Xp11.2 Inversion Resulting in False-negative TFE3 FISH. (28296677)
2017
5
The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape. (28523933)
2017
6
Evaluation of renal cell carcinoma histological subtype and fuhrman grade using (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography. (28523353)
2017
7
Context-dependent role for chromatin remodeling component PBRM1/BAF180 in clear cell renal cell carcinoma. (28092369)
2017
8
Periostin promotes migration and invasion of renal cell carcinoma through the integrin/focal adhesion kinase/c-Jun N-terminal kinase pathway. (28381189)
2017
9
Reduced expression of CXCR4, a novel renal cancer stem cell marker, is associated with high-grade renal cell carcinoma. (27638770)
2017
10
High expression of FUT3 is linked to poor prognosis in clear cell renal cell carcinoma. (28533485)
2017
11
Low level of PDZ domain containing 1 (PDZK1) predicts poor clinical outcome in patients with clear cell renal cell carcinoma. (27993630)
2017
12
Sarcomatoid Renal Cell Carcinoma and Collecting Duct Carcinoma: Discrimination From Common Renal Cell Carcinoma Subtypes and Benign RCC Mimics on Multiphasic MDCT. (28528853)
2017
13
Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments. (28531203)
2017
14
Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia. (28503240)
2017
15
Abdominal seeding of renal cell carcinoma: radiologic, pathologic, and prognostic features. (28084547)
2017
16
Validation of 34betaE12 immunoexpression in clear cell papillary renal cell carcinoma as a sensitive biomarker. (27923499)
2017
17
Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma. (27841868)
2017
18
Functional analysis of serum microRNAs miR-21 and miR-106a in renal cell carcinoma. (27814278)
2017
19
Downregulation of YAP in Clear Cell Renal Cell Carcinoma Contributes to Poor Prognosis and Progressive Features. (28249914)
2017
20
MUC13 overexpression in renal cell carcinoma plays a central role in tumor progression and drug resistance. (28205224)
2017
21
Androgen receptor (AR) promotes clear cell renal cell carcinoma (ccRCC) migration and invasion via altering the circHIAT1/miR-195-5p/29a-3p/29c-3p/CDC42 signals. (28089832)
2017
22
89Zr-bevacizumab PET: Potential Early Read Out for Efficacy of Everolimus in Metastatic Renal Cell Carcinoma Patients. (28082434)
2017
23
FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma. (27379982)
2017
24
Image-guided ablation of renal cell carcinoma. (28527529)
2017
25
Comparison of biexponential and monoexponential DWI in evaluation of Fuhrman grading of clear cell renal cell carcinoma. (28050950)
2017
26
VHL-TGFBI signaling is involved in the synergy between 5-aza-2'-deoxycytidine and paclitaxel against human renal cell carcinoma. (28534376)
2017
27
First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. (28515811)
2017
28
Benign MA1llerian Inclusions in Lymphadenectomies for Renal Cell Carcinoma: A Radiologic and Pathologic Mimic of Metastases. (28511950)
2017
29
Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis. (28081542)
2017
30
Comprehensive genomic and phenotypic characterization of germline FH deletion in hereditary leiomyomatosis and renal cell carcinoma. (28196407)
2017
31
Strategies to overcome therapeutic resistance in renal cell carcinoma. (28089416)
2017
32
Small (< 4 cm) Renal Tumors With Predominantly Low Signal Intensity on T2-Weighted Images: Differentiation of Minimal-Fat Angiomyolipoma From Renal Cell Carcinoma. (27824487)
2017
33
Different expression patterns of histone H3K27 demethylases in renal cell carcinoma and bladder cancer. (27983522)
2017
34
Thrombus-like Tumor of Renal Cell Carcinoma Mimicking Transitional Cell Carcinoma of Kidney: A Case Report. (27896135)
2017
35
High expression of the long non-coding RNA HEIRCC promotes Renal Cell Carcinoma metastasis by inducing epithelial-mesenchymal transition. (28030807)
2017
36
Interference with Tim-3 protein expression attenuates the invasion of clear cell renal cell carcinoma and aggravates anoikis. (28112366)
2017
37
Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study. (28532444)
2017
38
Spinal analgesia improves surgical outcome after open nephrectomy for renal cell carcinoma: a randomized controlled study. (28532200)
2017
39
PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness. (28522811)
2017
40
Synchronous Presentation of Renal Cell Carcinoma and Hodgkin Lymphoma in an Adolescent. (28092312)
2017
41
Upregulation of miR-21 expression is a valuable predicator of advanced clinicopathological features and poor prognosis in patients with renal cell carcinoma through the p53/p21a89cyclinA E2a89Bax/caspase-3 signaling pathway. (28184919)
2017
42
Xp11 Translocation Renal Cell Carcinomas (RCCs) With RBM10-TFE3 Gene Fusion Demonstrating Melanotic Features and Overlapping Morphology With t(6;11) RCC: Interest and Diagnostic Pitfall in Detecting a Paracentric Inversion of TFE3. (28288037)
2017
43
A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with Sunitinib. (28011500)
2017
44
Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma. (28061437)
2017
45
miR-148a suppresses human renal cell carcinoma malignancy by targeting AKT2. (27878305)
2017
46
Prognostic Value of Inflammatory and Nutritional Scores in Renal Cell Carcinoma After Nephrectomy. (28528087)
2017
47
Effect of Tumor Complexity and Technique on Efficacy and Complications after Percutaneous Microwave Ablation of Stage T1a Renal Cell Carcinoma: A Single-Center, Retrospective Study. (28076721)
2017
48
Downregulation of a novel long non-coding RNA, LOC389332, is associated with poor prognosis and tumor progression in clear cell renal cell carcinoma. (28450954)
2017
49
CA9 as a biomarker in preoperative biopsy of small solid renal masses for diagnosis of clear cell renal cell carcinoma. (27775441)
2017
50
Sclerosing TFEB-rearrangement renal cell carcinoma: a recurring histologic pattern. (27864122)
2017

Variations for Renal Cell Carcinoma

About this section

UniProtKB/Swiss-Prot genetic disease variations for Renal Cell Carcinoma:

70
id Symbol AA change Variation ID SNP ID
1FLCNp.Arg239CysVAR_066026rs78683075
2VHLp.Leu163ProVAR_034998rs28940297

Clinvar genetic disease variations for Renal Cell Carcinoma:

5 (show all 22)
id Gene Variation Type Significance SNP ID Assembly Location
1TP53NM_ 000546.5(TP53): c.722C> T (p.Ser241Phe)SNVPathogenic/ Likely pathogenicrs28934573GRCh37Chr 17, 7577559: 7577559
2TP53NM_ 000546.5(TP53): c.659A> G (p.Tyr220Cys)SNVPathogenic/ Likely pathogenicrs121912666GRCh37Chr 17, 7578190: 7578190
3TP53NM_ 000546.5(TP53): c.638G> A (p.Arg213Gln)SNVPathogenic/ Likely pathogenicrs587778720GRCh38Chr 17, 7674893: 7674893
4PIK3CANM_ 006218.3(PIK3CA): c.3140A> G (p.His1047Arg)SNVPathogenic/ Likely pathogenicrs121913279GRCh37Chr 3, 178952085: 178952085
5PIK3CANM_ 006218.3(PIK3CA): c.3140A> T (p.His1047Leu)SNVPathogenic/ Likely pathogenicrs121913279GRCh37Chr 3, 178952085: 178952085
6PIK3CANM_ 006218.3(PIK3CA): c.1633G> A (p.Glu545Lys)SNVPathogenic/ Likely pathogenicrs104886003GRCh37Chr 3, 178936091: 178936091
7PIK3CANM_ 006218.3(PIK3CA): c.1634A> G (p.Glu545Gly)SNVPathogenic/ Likely pathogenicrs121913274GRCh37Chr 3, 178936092: 178936092
8NRASNM_ 002524.4(NRAS): c.182A> G (p.Gln61Arg)SNVPathogenic/ Likely pathogenicrs11554290GRCh37Chr 1, 115256529: 115256529
9TP53NM_ 000546.5(TP53): c.422G> A (p.Cys141Tyr)SNVPathogenic/ Likely pathogenicrs587781288GRCh37Chr 17, 7578508: 7578508
10TP53NM_ 000546.5(TP53): c.844C> G (p.Arg282Gly)SNVPathogenic/ Likely pathogenicrs28934574GRCh37Chr 17, 7577094: 7577094
11TP53NM_ 000546.5(TP53): c.842A> G (p.Asp281Gly)SNVPathogenic/ Likely pathogenicrs587781525GRCh37Chr 17, 7577096: 7577096
12PIK3CANM_ 006218.3(PIK3CA): c.1634A> C (p.Glu545Ala)SNV, HaplotypePathogenic/ Likely pathogenicrs121913274GRCh37Chr 3, 178936092: 178936092
13TP53NM_ 000546.5(TP53): c.842A> T (p.Asp281Val)SNVPathogenic/ Likely pathogenicrs587781525GRCh38Chr 17, 7673778: 7673778
14TP53NM_ 000546.5(TP53): c.824G> A (p.Cys275Tyr)SNVPathogenic/ Likely pathogenicrs863224451GRCh38Chr 17, 7673796: 7673796
15PIK3CANM_ 006218.3(PIK3CA): c.1635G> T (p.Glu545Asp)SNVPathogenic/ Likely pathogenicrs121913275GRCh37Chr 3, 178936093: 178936093
16NRASNM_ 002524.4(NRAS): c.182A> C (p.Gln61Pro)SNVPathogenic/ Likely pathogenicrs11554290GRCh37Chr 1, 115256529: 115256529
17NRASNM_ 002524.4(NRAS): c.183A> T (p.Gln61His)SNVPathogenic/ Likely pathogenicrs121913255GRCh37Chr 1, 115256528: 115256528
18NRASNM_ 002524.4(NRAS): c.182A> T (p.Gln61Leu)SNVPathogenic/ Likely pathogenicrs11554290GRCh37Chr 1, 115256529: 115256529
19PIK3CANM_ 006218.3(PIK3CA): c.1633G> C (p.Glu545Gln)SNVPathogenic/ Likely pathogenicrs104886003GRCh37Chr 3, 178936091: 178936091
20PIK3CANM_ 006218.3(PIK3CA): c.3139C> T (p.His1047Tyr)SNVPathogenic/ Likely pathogenicrs121913281GRCh37Chr 3, 178952084: 178952084
21NRASNM_ 002524.4(NRAS): c.181C> A (p.Gln61Lys)SNVPathogenic/ Likely pathogenicrs121913254GRCh37Chr 1, 115256530: 115256530
22PTENNM_ 000314.6(PTEN): c.389G> A (p.Arg130Gln)SNVPathogenic/ Likely pathogenicrs121909229GRCh37Chr 10, 89692905: 89692905

Cosmic variations for Renal Cell Carcinoma:

8 (show top 50)    (show all 957)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM26614RABGAP1kidney,NS,carcinoma,renal cellc.1533T>Ap.H511Q48
2COSM30531COPS4kidney,NS,carcinoma,renal cellc.385G>Cp.G129R48
3COSM30471ARHGAP20kidney,NS,carcinoma,renal cellc.1355A>Gp.D452G48
4COSM30474TRIOkidney,NS,carcinoma,renal cellc.9008A>Gp.N3003S48
5COSM25654CDC5Lkidney,NS,carcinoma,renal cellc.1196G>Ap.R399Q48
6COSM25676VHLkidney,NS,carcinoma,renal cellc.485G>Tp.C162F48
7COSM28415DOCK1kidney,NS,carcinoma,renal cellc.1306G>Tp.D436Y48
8COSM30502ITPR3kidney,NS,carcinoma,renal cellc.4574G>Tp.C1525F48
9COSM27618KMT2Akidney,NS,carcinoma,renal cellc.5711C>Tp.A1904V48
10COSM30530PTPN22kidney,NS,carcinoma,renal cellc.209G>Cp.R70P48
11COSM26594RNF144Akidney,NS,carcinoma,renal cellc.410C>Tp.A137V48
12COSM27269UMPSkidney,NS,carcinoma,renal cellc.528G>Ap.L176L48
13COSM26987RGS7kidney,NS,carcinoma,renal cellc.169T>Cp.F57L48
14COSM30443TNFRSF19kidney,NS,carcinoma,clear cell renal cell carcinomac.181-1G>Tp.?31
15COSM26973BABAM2kidney,NS,carcinoma,clear cell renal cell carcinomac.546C>Tp.S182S31
16COSM26976ATRXkidney,NS,carcinoma,clear cell renal cell carcinomac.4957G>Cp.V1653L31
17COSM26993PPARGkidney,NS,carcinoma,clear cell renal cell carcinomac.11C>Gp.T4S31
18COSM14400VHLkidney,NS,carcinoma,clear cell renal cell carcinomac.194C>Tp.S65L31
19COSM26985BTG2kidney,NS,carcinoma,clear cell renal cell carcinomac.223G>Ap.D75N31
20COSM25709PUS10kidney,NS,carcinoma,clear cell renal cell carcinomac.197C>Gp.P66R31
21COSM30293VHLkidney,NS,carcinoma,clear cell renal cell carcinomac.586A>Tp.K196*31
22COSM30489KMT2Dkidney,NS,carcinoma,clear cell renal cell carcinomac.1311G>Tp.E437D31
23COSM17734VHLkidney,NS,carcinoma,clear cell renal cell carcinomac.304C>Gp.P102A31
24COSM691METkidney,NS,carcinoma,papillary renal cell carcinomac.3803T>Cp.M1268T31
25COSM1732041PBRM1kidney,NS,carcinoma,clear cell renal cell carcinomac.1612T>Cp.S538P31
26COSM36358VHLkidney,NS,carcinoma,clear cell renal cell carcinomac.341-11T>Ap.?31
27COSM17658VHLkidney,NS,carcinoma,clear cell renal cell carcinomac.286C>Tp.Q96*31
28COSM5011046COL6A3kidney,NS,carcinoma,papillary renal cell carcinomac.5464G>Ap.E1822K31
29COSM249379CREBBPkidney,NS,carcinoma,clear cell renal cell carcinomac.5418G>Cp.K1806N31
30COSM34007VHLkidney,NS,carcinoma,clear cell renal cell carcinomac.227T>Cp.F76S31
31COSM5036PTENkidney,NS,carcinoma,clear cell renal cell carcinomac.202T>Cp.Y68H31
32COSM422817PBRM1kidney,NS,carcinoma,clear cell renal cell carcinomac.3601G>Tp.E1201*31
33COSM266367DDX54kidney,NS,carcinoma,papillary renal cell carcinomac.1543G>Ap.A515T31
34COSM249579KCNA3kidney,NS,carcinoma,clear cell renal cell carcinomac.1018T>Ap.F340I31
35COSM307605CRISPLD1kidney,NS,carcinoma,clear cell renal cell carcinomac.463T>Ap.Y155N31
36COSM249280VHLkidney,NS,carcinoma,clear cell renal cell carcinomac.264G>Ap.W88*31
37COSM18023VHLkidney,NS,carcinoma,clear cell renal cell carcinomac.486C>Gp.C162W31
38COSM17875VHLkidney,NS,carcinoma,clear cell renal cell carcinomac.234T>Gp.N78K31
39COSM30212VHLkidney,NS,carcinoma,clear cell renal cell carcinomac.202T>Cp.S68P31
40COSM422772PBRM1kidney,NS,carcinoma,clear cell renal cell carcinomac.1443+1G>Tp.?31
41COSM18276VHLkidney,NS,carcinoma,clear cell renal cell carcinomac.406T>Gp.F136V31
42COSM249426IL6STkidney,NS,carcinoma,clear cell renal cell carcinomac.2125A>Tp.K709*31
43COSM14407VHLkidney,NS,carcinoma,clear cell renal cell carcinomac.388G>Cp.V130L31
44COSM18212VHLkidney,NS,carcinoma,clear cell renal cell carcinomac.491A>Cp.Q164P31
45COSM14311VHLkidney,NS,carcinoma,clear cell renal cell carcinomac.499C>Tp.R167W31
46COSM14380VHLkidney,NS,carcinoma,clear cell renal cell carcinomac.548C>Ap.S183*31
47COSM30295VHLkidney,NS,carcinoma,clear cell renal cell carcinomac.341-2A>Gp.?31
48COSM4760527KSR2kidney,NS,carcinoma,papillary renal cell carcinomac.1679C>Tp.T560M31
49COSM18015VHLkidney,NS,carcinoma,clear cell renal cell carcinomac.194C>Ap.S65*31
50COSM249520DDX21kidney,NS,carcinoma,clear cell renal cell carcinomac.689C>Gp.A230G31

Copy number variations for Renal Cell Carcinoma from CNVD:

6 (show top 50)    (show all 1298)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
114830111045231105523GainRenal cell carcinoma
21676611365851113659511GainRenal cell carcinoma
31677011370317613704176LossRenal cell carcinoma
41677311372282913723829GainRenal cell carcinoma
51921611492519915393109LossRenal cell carcinoma
6244281180300000185800000Copy numberRenal cell carcinoma
7263251199103044199104044GainRenal cell carcinoma
8273351207179162207180162GainRenal cell carcinoma
9278611214500000224100000GainRenal cell carcinoma
103008812400000026000000LossRenal cell carcinoma
113104212486282424867531LossRCAN3Renal cell carcinoma
123152712800000030200000LossRenal cell carcinoma
1333893150000007000000LossRenal cell carcinoma
144218910300000017300000Copy numberRenal cell carcinoma
1542932104230000052900000Copy numberRenal cell carcinoma
164943211106916419134173875LossRenal cell carcinoma
174970511110400000121200000Copy numberRenal cell carcinoma
1851840111318272113183721GainRenal cell carcinoma
1951843111318485613185856LossRenal cell carcinoma
2052861112100000057000000GainRenal cell carcinoma
2153056112364258423643584GainRenal cell carcinoma
2253595113100000043500000Copy numberRenal cell carcinoma
2353953113531777135318771GainRenal cell carcinoma
24604901187000000107000000GainRenal cell carcinoma
2564438121280000014800000Copy numberRenal cell carcinoma
2667031123500000069000000GainRenal cell carcinoma
27670431235400000132349534GainRenal cell carcinoma
2869398125490000058100000Copy numberRenal cell carcinoma
29725321282000000100000000GainRenal cell carcinoma
3075379131950000023300000LossRenal cell carcinoma
3175593132154857821635655Copy numberRenal cell carcinoma
32828011415600000106368585Copy numberRenal cell carcinoma
33828181415600000106368585LossRenal cell carcinoma
34831871419387587106241517LossRenal cell carcinoma
3585229144100000048000000GainRenal cell carcinoma
3687551147455021974587988LossMLH3Renal cell carcinoma
3788249148869226889155247LossFOXN3Renal cell carcinoma
3888312148980000091900000Copy numberRenal cell carcinoma
398917015100153615100154615GainRenal cell carcinoma
4090158152023352320234523GainRenal cell carcinoma
4190187152035918220360182GainRenal cell carcinoma
4290188152035922920360229GainRenal cell carcinoma
4390209152043926020440260LossRenal cell carcinoma
4490210152044215220442452LossRenal cell carcinoma
4590214152044991320450913GainRenal cell carcinoma
4690215152045011520451115LossRenal cell carcinoma
4790218152053587720536877LossRenal cell carcinoma
4890224152061127120612271LossRenal cell carcinoma
4990229152064379220644792LossRenal cell carcinoma
5090232152066617920666479LossRenal cell carcinoma

Expression for genes affiliated with Renal Cell Carcinoma

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Renal Cell Carcinoma patients vs. healthy controls: 35 (show all 278)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1SLC12A1solute carrier family 12 (sodium/potassium/chloride transporter), member 1Kidney-9.350.000
2CALB1calbindin 1, 28kDaKidney-8.950.000
3FXYD4FXYD domain containing ion transport regulator 4Kidney-8.290.000
4CLDN8claudin 8Kidney-8.200.000
5KCNJ1potassium channel, inwardly rectifying subfamily J, member 1Kidney-8.200.000
6NPHS2nephrosis 2, idiopathic, steroid-resistant (podocin)Kidney-8.180.000
7MUC15mucin 15, cell surface associatedKidney-7.960.000
8SCNN1Gsodium channel, non voltage gated 1 gamma subunitKidney-7.910.000
9HPD4-hydroxyphenylpyruvate dioxygenaseKidney-7.780.000
10FABP1fatty acid binding protein 1, liverKidney-7.740.000
11DNASE1deoxyribonuclease IKidney-7.590.000
12SLC7A13solute carrier family 7 (anionic amino acid transporter), member 13Kidney-7.290.000
13ANGPTL4angiopoietin-like 4Kidney+7.250.000
14TNFAIP6tumor necrosis factor, alpha-induced protein 6Kidney+7.160.000
15ATP6V0A4ATPase, H+ transporting, lysosomal V0 subunit a4Kidney-7.130.000
16PCP4Purkinje cell protein 4Kidney-7.130.000
17KNG1kininogen 1Kidney-7.120.000
18TYRP1tyrosinase-related protein 1Kidney-7.100.000
19FGF9fibroblast growth factor 9Kidney-6.990.000
20EGFepidermal growth factorKidney-6.920.000
21RALYLRALY RNA binding protein-likeKidney-6.810.000
22PVALBparvalbuminKidney-6.730.000
23KCNJ10potassium channel, inwardly rectifying subfamily J, member 10Kidney-6.690.000
24TMEM213transmembrane protein 213Kidney-6.640.000
25SLC22A8solute carrier family 22 (organic anion transporter), member 8Kidney-6.580.000
26IRX2iroquois homeobox 2Kidney-6.560.000
27SLC26A7solute carrier family 26 (anion exchanger), member 7Kidney-6.560.000
28SLC4A1solute carrier family 4 (anion exchanger), member 1 (Diego blood group)Kidney-6.530.000
29GPC5glypican 5Kidney-6.530.000
30RHCGRh family, C glycoproteinKidney-6.520.000
31SOSTsclerostinKidney-6.510.000
32SFRP1secreted frizzled-related protein 1Kidney-6.490.000
33HEPACAM2HEPACAM family member 2Kidney-6.450.000
34NELL1neural EGFL like 1Kidney-6.380.000
35SERPINA5serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5Kidney-6.340.000
36RAB25RAB25, member RAS oncogene familyKidney-6.320.000
37TMPRSS2transmembrane protease, serine 2Kidney-6.310.000
38TMEM52Btransmembrane protein 52BKidney-6.280.000
39ERBB4erb-b2 receptor tyrosine kinase 4Kidney-6.260.000
40SOSTDC1sclerostin domain containing 1Kidney-6.250.000
41SH3GL2SH3-domain GRB2-like 2Kidney-6.160.000
42ALDOBaldolase B, fructose-bisphosphateKidney-6.130.003
43APOC1apolipoprotein C-IKidney+6.110.000
44UMODuromodulinKidney-6.070.000
45NPTX2neuronal pentraxin IIKidney+6.050.000
46LOC284578uncharacterized LOC284578Kidney-6.020.000
47ESRRBestrogen-related receptor betaKidney-5.990.000
48SLC13A3solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 3Kidney-5.960.001
49TSPAN8tetraspanin 8Kidney-5.960.000
50WNK4WNK lysine deficient protein kinase 4Kidney-5.940.000
51DIO1deiodinase, iodothyronine, type IKidney-5.930.000
52PTHLHparathyroid hormone-like hormoneKidney+5.880.001
53NDUFA4L2NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4-like 2Kidney+5.760.000
54ATP6V1G3ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G3Kidney-5.730.000
55NOS1nitric oxide synthase 1 (neuronal)Kidney-5.730.000
56FABP7fatty acid binding protein 7, brainKidney+5.710.042
57SIM2single-minded family bHLH transcription factor 2Kidney-5.660.000
58XPNPEP2X-prolyl aminopeptidase (aminopeptidase P) 2, membrane-boundKidney-5.650.000
59G6PCglucose-6-phosphatase, catalytic subunitKidney-5.640.013
60SCNN1Asodium channel, non voltage gated 1 alpha subunitKidney-5.630.002
61ATP6V1B1ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B1Kidney-5.620.000
62HSD11B2hydroxysteroid (11-beta) dehydrogenase 2Kidney-5.600.000
63CCL20chemokine (C-C motif) ligand 20Kidney+5.550.007
64HS6ST2heparan sulfate 6-O-sulfotransferase 2Kidney-5.520.000
65CDCA2cell division cycle associated 2Kidney+5.520.000
66DPEP1dipeptidase 1 (renal)Kidney-5.490.000
67SLC4A9solute carrier family 4, sodium bicarbonate cotransporter, member 9Kidney-5.490.000
68C16orf89chromosome 16 open reading frame 89Kidney-5.480.000
69CTXN3cortexin 3Kidney-5.470.001
70LOC285556uncharacterized LOC285556Kidney-5.470.000
71FAM3Bfamily with sequence similarity 3, member BKidney-5.430.000
72HRGhistidine-rich glycoproteinKidney-5.400.000
73PLGplasminogenKidney-5.400.000
74STC2stanniocalcin 2Kidney+5.390.000
75ENPP6ectonucleotide pyrophosphatase/phosphodiesterase 6Kidney-5.380.000
76MST1Lmacrophage stimulating 1-likeKidney-5.340.000
77PAHphenylalanine hydroxylaseKidney-5.320.003
78MFSD4major facilitator superfamily domain containing 4Kidney-5.310.000
79SCNN1Bsodium channel, non voltage gated 1 beta subunitKidney-5.290.000
80PRDM16PR domain containing 16Kidney-5.290.000
81FAM151Afamily with sequence similarity 151, member AKidney-5.290.004
82MALmal, T-cell differentiation proteinKidney-5.290.001
83CA10carbonic anhydrase XKidney-5.290.000
84GRM1glutamate receptor, metabotropic 1Kidney-5.280.000
85RANBP3LRAN binding protein 3-likeKidney-5.270.000
86CLCNKBchloride channel, voltage-sensitive KbKidney-5.260.000
87NRKNik related kinaseKidney-5.260.000
88VTCN1V-set domain containing T cell activation inhibitor 1Kidney-5.260.000
89ESRP1epithelial splicing regulatory protein 1Kidney-5.250.001
90TOP2Atopoisomerase (DNA) II alphaKidney+5.240.000
91CYP4F2cytochrome P450, family 4, subfamily F, polypeptide 2Kidney-5.210.000
92ZNF44zinc finger protein 44Kidney-5.190.000
93DUSP9dual specificity phosphatase 9Kidney-5.150.000
94AQP2aquaporin 2 (collecting duct)Kidney-5.150.000
95SLC22A7solute carrier family 22 (organic anion transporter), member 7Kidney-5.130.008
96VGLL1vestigial-like family member 1Kidney-5.120.000
97EGLN3egl-9 family hypoxia-inducible factor 3Kidney+5.120.000
98DMRT2doublesex and mab-3 related transcription factor 2Kidney-5.110.000
99TACSTD2tumor-associated calcium signal transducer 2Kidney-5.110.000
100CASRcalcium-sensing receptorKidney-5.110.000
101SLC13A2solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 2Kidney-5.110.000
102UPP2uridine phosphorylase 2Kidney-5.100.000
103PLPPR1phospholipid phosphatase related 1Kidney-5.080.000
104CRYAAcrystallin, alpha AKidney-5.080.000
105NKG7natural killer cell granule protein 7Kidney+5.070.000
106C7complement component 7Kidney-5.070.002
107RALGAPA2Ral GTPase activating protein, alpha subunit 2 (catalytic)Kidney-5.050.000
108NNMTnicotinamide N-methyltransferaseKidney+5.050.000
109MYO3Bmyosin IIIBKidney-5.050.001
110CWH43cell wall biogenesis 43 C-terminal homologKidney-5.030.002
111ADH1Balcohol dehydrogenase 1B (class I), beta polypeptideKidney-5.020.001
112TMEM61transmembrane protein 61Kidney-4.990.000
113SLC22A12solute carrier family 22 (organic anion/urate transporter), member 12Kidney-4.970.001
114ELF5E74-like factor 5 (ets domain transcription factor)Kidney-4.960.000
115TOX3TOX high mobility group box family member 3Kidney-4.940.019
116FLJ22763uncharacterized LOC401081Kidney-4.940.006
117FABP6fatty acid binding protein 6, ilealKidney+4.940.005
118TCEAL2transcription elongation factor A (SII)-like 2Kidney-4.920.003
119CA9carbonic anhydrase IXKidney+4.920.000
120LOC149703uncharacterized LOC149703Kidney-4.920.001
121TMEM45Btransmembrane protein 45BKidney-4.920.003
122EHFets homologous factorKidney-4.900.000
123ATP6V1C2ATPase, H+ transporting, lysosomal 42kDa, V1 subunit C2Kidney-4.900.000
124ISG20interferon stimulated exonuclease gene 20kDaKidney+4.890.000
125BMPR1Bbone morphogenetic protein receptor, type IBKidney-4.880.001
126SLC22A6solute carrier family 22 (organic anion transporter), member 6Kidney-4.870.011
127SCN2Asodium channel, voltage gated, type II alpha subunitKidney-4.870.001
128SLC7A8solute carrier family 7 (amino acid transporter light chain, L system), member 8Kidney-4.860.000
129KLRG2killer cell lectin-like receptor subfamily G, member 2Kidney-4.840.000
130GGT6gamma-glutamyltransferase 6Kidney-4.830.000
131ACPPacid phosphatase, prostateKidney-4.830.000
132PROM2prominin 2Kidney-4.770.000
133PLCXD3phosphatidylinositol-specific phospholipase C, X domain containing 3Kidney-4.770.000
134CLDN16claudin 16Kidney-4.770.000
135AFMafaminKidney-4.760.001
136KCNE1potassium channel, voltage gated subfamily E regulatory beta subunit 1Kidney-4.760.000
137CLIC5chloride intracellular channel 5Kidney-4.730.000
138ADGRF1adhesion G protein-coupled receptor F1Kidney-4.720.000
139GATA3GATA binding protein 3Kidney-4.720.002
140ATP6V0D2ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d2Kidney-4.710.000
141HK2hexokinase 2Kidney+4.710.000
142TFCP2L1transcription factor CP2-like 1Kidney-4.710.000
143GABRA2gamma-aminobutyric acid (GABA) A receptor, alpha 2Kidney-4.700.000
144CLDN19claudin 19Kidney-4.680.000
145PPP1R1Aprotein phosphatase 1, regulatory (inhibitor) subunit 1AKidney-4.670.021
146KISS1RKISS1 receptorKidney+4.670.001
147ADH1Calcohol dehydrogenase 1C (class I), gamma polypeptideKidney-4.650.000
148TFAP2Btranscription factor AP-2 beta (activating enhancer binding protein 2 beta)Kidney-4.630.000
149PTGER1prostaglandin E receptor 1 (subtype EP1), 42kDaKidney-4.620.000
150STAP1signal transducing adaptor family member 1Kidney-4.610.000
151ARL11ADP-ribosylation factor-like 11Kidney+4.600.000
152LINC00982long intergenic non-protein coding RNA 982Kidney-4.600.000
153CHL1cell adhesion molecule L1-likeKidney-4.600.001
154FOXI1forkhead box I1Kidney-4.590.000
155C5orf46chromosome 5 open reading frame 46Kidney+4.590.016
156ANKRD2ankyrin repeat domain 2 (stretch responsive muscle)Kidney-4.580.001
157ALBalbuminKidney-4.570.000
158L1CAML1 cell adhesion moleculeKidney-4.570.004
159PDGFRAplatelet-derived growth factor receptor, alpha polypeptideKidney-4.560.009
160FGF1fibroblast growth factor 1 (acidic)Kidney-4.560.000
161C3complement component 3Kidney+4.550.000
162TMEM207transmembrane protein 207Kidney-4.550.000
163CTHRC1collagen triple helix repeat containing 1Kidney+4.540.000
164KLHL14kelch-like family member 14Kidney-4.530.001
165ANGPTL1angiopoietin-like 1Kidney-4.530.002
166SLC12A3solute carrier family 12 (sodium/chloride transporter), member 3Kidney-4.500.000
167CD300ACD300a moleculeKidney+4.490.001
168TMEM178Atransmembrane protein 178AKidney-4.480.000
169SEMA6Dsema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6DKidney-4.470.000
170CCL18chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated)Kidney+4.450.012
171TCF21transcription factor 21Kidney-4.450.002
172SLAMF7SLAM family member 7Kidney+4.450.001
173PDE1Aphosphodiesterase 1A, calmodulin-dependentKidney-4.440.000
174MIR155HGMIR155 host geneKidney+4.440.001
175SOWAHAsosondowah ankyrin repeat domain family member AKidney-4.440.007
176HMGCS23-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial)Kidney-4.430.036
177RBP4retinol binding protein 4, plasmaKidney-4.430.009
178SLFN13schlafen family member 13Kidney+4.320.000
179SLC16A3solute carrier family 16 (monocarboxylate transporter), member 3Kidney+4.240.000
180FAM26Ffamily with sequence similarity 26, member FKidney+4.180.000
181SPAG4sperm associated antigen 4Kidney+4.130.000
182EHD2EH-domain containing 2Kidney+4.120.000
183CXCL9chemokine (C-X-C motif) ligand 9Kidney+4.110.001
184LOXlysyl oxidaseKidney+4.100.000
185CCNE2cyclin E2Kidney+4.080.000
186ENO2enolase 2 (gamma, neuronal)Kidney+4.080.000
187COL23A1collagen, type XXIII, alpha 1Kidney+4.030.003
188RGS1regulator of G-protein signaling 1Kidney+4.030.000
189CD86CD86 moleculeKidney+3.990.000
190CYP2J2cytochrome P450, family 2, subfamily J, polypeptide 2Kidney+3.990.023
191HAPLN1hyaluronan and proteoglycan link protein 1Kidney+3.980.009
192TLR8toll-like receptor 8Kidney+3.980.000
193ST8SIA4ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4Kidney+3.900.000
194AHNAK2AHNAK nucleoprotein 2Kidney+3.900.000
195BIRC3baculoviral IAP repeat containing 3Kidney+3.880.000
196TTKTTK protein kinaseKidney+3.880.000
197HIST1H2AGhistone cluster 1, H2agKidney+3.870.007
198LILRB2leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 2Kidney+3.870.000
199LOC100289026uncharacterized LOC100289026Kidney+3.860.006
200C4orf47chromosome 4 open reading frame 47Kidney+3.850.000
201INHBBinhibin, beta BKidney+3.840.001
202PLA2G7phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma)Kidney+3.840.003
203CPceruloplasmin (ferroxidase)Kidney+3.830.021
204BRIP1BRCA1 interacting protein C-terminal helicase 1Kidney+3.830.003
205HMHA1histocompatibility (minor) HA-1Kidney+3.830.000
206GAS2L3growth arrest-specific 2 like 3Kidney+3.830.000
207TEX11testis expressed 11Kidney+3.790.029
208HILPDAhypoxia inducible lipid droplet-associatedKidney+3.790.000
209TREM2triggering receptor expressed on myeloid cells 2Kidney+3.790.000
210BHLHE41basic helix-loop-helix family, member e41Kidney+3.720.000
211TMCC1transmembrane and coiled-coil domain family 1Kidney+3.720.000
212KIF20Akinesin family member 20AKidney+3.720.000
213TPX2TPX2, microtubule-associatedKidney+3.700.000
214SEC16BSEC16 homolog B, endoplasmic reticulum export factorKidney+3.700.000
215PVT1Pvt1 oncogene (non-protein coding)Kidney+3.690.000
216TRDV3T cell receptor delta variable 3Kidney+3.640.000
217HTRA4HtrA serine peptidase 4Kidney+3.630.005
218TMEM45Atransmembrane protein 45AKidney+3.630.016
219SLC6A3solute carrier family 6 (neurotransmitter transporter), member 3Kidney+3.620.012
220CDKN2Acyclin-dependent kinase inhibitor 2AKidney+3.590.000
221RHOHras homolog family member HKidney+3.590.000
222PTPN22protein tyrosine phosphatase, non-receptor type 22 (lymphoid)Kidney+3.590.003
223NETO2neuropilin (NRP) and tolloid (TLL)-like 2Kidney+3.570.001
224NEK2NIMA-related kinase 2Kidney+3.570.000
225P2RX7purinergic receptor P2X, ligand gated ion channel, 7Kidney+3.570.000
226SIRPGsignal-regulatory protein gammaKidney+3.540.015
227ALOX5arachidonate 5-lipoxygenaseKidney+3.530.000
228TRDT cell receptor delta locusKidney+3.520.000
229TEN1TEN1 CST complex subunitKidney+3.500.000
230SLAMF8SLAM family member 8Kidney+3.500.001
231CCR5chemokine (C-C motif) receptor 5 (gene/pseudogene)Kidney+3.490.000
232BIN2bridging integrator 2Kidney+3.460.000
233TNFRSF4tumor necrosis factor receptor superfamily, member 4Kidney+3.440.001
234FCGR2CFc fragment of IgG, low affinity IIc, receptor for (CD32) (gene/pseudogene)Kidney+3.420.000
235BRCA2breast cancer 2, early onsetKidney+3.390.000
236SLC17A4solute carrier family 17, member 4Kidney+3.380.019
237CXCL10chemokine (C-X-C motif) ligand 10Kidney+3.380.007
238PIK3R5phosphoinositide-3-kinase, regulatory subunit 5Kidney+3.370.000
239IGFBP3insulin-like growth factor binding protein 3Kidney+3.360.000
240VSIG1V-set and immunoglobulin domain containing 1Kidney+3.350.013
241ASPMabnormal spindle microtubule assemblyKidney+3.330.004
242HIST1H3Hhistone cluster 1, H3hKidney+3.320.012
243GIT2G protein-coupled receptor kinase interacting ArfGAP 2Kidney+3.300.000
244CDKN3cyclin-dependent kinase inhibitor 3Kidney+3.290.000
245FANCIFanconi anemia, complementation group IKidney+3.270.000
246CDC25Ccell division cycle 25CKidney+3.260.010
247DUSP4dual specificity phosphatase 4Kidney+3.260.003
248CCL5chemokine (C-C motif) ligand 5Kidney+3.240.003
249DTLdenticleless E3 ubiquitin protein ligase homolog (Drosophila)Kidney+3.230.000
250CXCL11chemokine (C-X-C motif) ligand 11Kidney+3.210.010
251CST7cystatin F (leukocystatin)Kidney+3.200.004
252TNFSF13Btumor necrosis factor (ligand) superfamily, member 13bKidney+3.190.000
253RAC2ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2)Kidney+3.190.002
254PARVGparvin, gammaKidney+3.180.000
255BUB1BUB1 mitotic checkpoint serine/threonine kinaseKidney+3.180.012
256ZNF395zinc finger protein 395Kidney+3.170.021
257MCM10minichromosome maintenance 10 replication initiation factorKidney+3.170.007
258TMEM44transmembrane protein 44Kidney+3.150.000
259LOXL2lysyl oxidase-like 2Kidney+3.140.003
260CD8ACD8a moleculeKidney+3.140.011
261XCL1chemokine (C motif) ligand 1Kidney+3.120.002
262VNN2vanin 2Kidney+3.110.005
263CENPKcentromere protein KKidney+3.110.001
264RRM2ribonucleotide reductase M2Kidney+3.090.006
265CHPF2chondroitin polymerizing factor 2Kidney+3.090.000
266CRTAMcytotoxic and regulatory T cell moleculeKidney+3.080.012
267SCDstearoyl-CoA desaturase (delta-9-desaturase)Kidney+3.080.001
268IL7Rinterleukin 7 receptorKidney+3.070.018
269LPCAT1lysophosphatidylcholine acyltransferase 1Kidney+3.050.000
270LCKLCK proto-oncogene, Src family tyrosine kinaseKidney+3.050.000
271SAP30Sin3A-associated protein, 30kDaKidney+3.050.000
272PCSK6proprotein convertase subtilisin/kexin type 6Kidney+3.050.025
273TEAD4TEA domain family member 4Kidney+3.050.000
274SCARB1scavenger receptor class B, member 1Kidney+3.040.001
275CLEC12AC-type lectin domain family 12, member AKidney+3.030.003
276MYO9Bmyosin IXBKidney+3.010.001
277LILRB1leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1Kidney+3.010.002
278PRR11proline rich 11Kidney+3.000.001

Search GEO for disease gene expression data for Renal Cell Carcinoma.

Pathways for genes affiliated with Renal Cell Carcinoma

About this section

GO Terms for genes affiliated with Renal Cell Carcinoma

About this section

Cellular components related to Renal Cell Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1transcription factor complexGO:000566710.5EPAS1, HIF1A, HNF1A, HNF1B

Biological processes related to Renal Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 16)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of transcription from RNA polymerase II promoterGO:004594411.3EPAS1, FLCN, HIF1A, HNF1A, HNF1B, IL2
2negative regulation of apoptotic processGO:004306611.3HIF1A, HNF1B, IL2, OGG1, VEGFA, VHL
3branching morphogenesis of an epithelial tubeGO:004875411.3HNF1B, MET, VEGFA
4negative regulation of Rho protein signal transductionGO:003502411.3FLCN, KANK1, MET
5positive regulation of transcription, DNA-templatedGO:004589311.3HIF1A, HNF1A, HNF1B, TFE3, VHL
6positive regulation of cell adhesionGO:004578511.3FLCN, TFE3, VEGFA
7cellular response to hypoxiaGO:007145611.3EPAS1, HIF1A, VEGFA
8camera-type eye morphogenesisGO:004859311.3HIF1A, VEGFA
9positive regulation of transcription initiation from RNA polymerase II promoterGO:006026111.3HNF1A, HNF1B
10regulation of transcription from RNA polymerase II promoter in response to hypoxiaGO:006141811.3CA9, EPAS1, HIF1A, VEGFA, VHL
11regulation of pronephros sizeGO:003556511.3HNF1A, HNF1B
12positive regulation of transcription from RNA polymerase II promoter in response to hypoxiaGO:006141911.3HIF1A, VEGFA
13positive regulation of vascular endothelial growth factor receptor signaling pathwayGO:003094911.2HIF1A, VEGFA
14regulation of transcription from RNA polymerase II promoter in response to oxidative stressGO:004361911.2EPAS1, HIF1A
15regulation of transcription, DNA-templatedGO:000635510.8EPAS1, FHIT, HIF1A, HNF1A, HNF1B, KANK1
16surfactant homeostasisGO:004312910.5EPAS1, VEGFA

Molecular functions related to Renal Cell Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1protein dimerization activityGO:004698311.2EPAS1, HIF1A, HNF1A, TFE3
2protein heterodimerization activityGO:004698211.2EPAS1, HIF1A, HNF1A, HNF1B, VEGFA
3transcription factor bindingGO:000813411.1EPAS1, HIF1A, HNF1A, VHL
4transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific bindingGO:000107710.5EPAS1, HIF1A, HNF1A, TFE3

Sources for Renal Cell Carcinoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet